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ABSTRACT
In both, normal and stress erythropoiesis in hematopoietic organs, erythroblasts
proliferate and differentiate while associated with a central macrophage. This distinct
structure has been termed erythroblastic island. Growing evidence revealed the crucial role of
macrophage/erythroblast and erythroblast/erythroblast interactions within erythroblastic
islands during erythropoiesis. The formation and stability of this special niche depend on
various adhesion molecules that are believed to mediate both erythroblast/erythroblast and
erythroblast/macrophage interactions. Among these molecules, integrin family proteins,
expressed by both central macrophage and erythroblasts have been identified to be involved in
the attachment of macrophage with erythroblasts.
The Landsteiner-Weiner blood group glycoprotein protein intercellular adhesion
molecule-4 (ICAM-4) has been shown to bind to integrin heterodimers such as αLβ2, αMβ2,
αIIbβ3, αvβ1, αvβ5 and αvβ3. Among these, the interaction of ICAM with αv appeared to be
involved in the formation and maintenance of the integrity of erythroblastic island. However,
which β integrin is the heterodimerization partner of αv remained unknown.
By comparing stress erythropoiesis in the anemic integrin β3 lacking mice and
transgenic mice with constant overexpression of human erythropoietin (tg 6) we delineated
the role of integrin β3 for stabilization of erythroblastic islands. Integrin β3 lacking mice
showed reduced numbers of erythroblast per erythropoietic island and a lower percentage of
the late stage erythroblasts and premature reticulocytes in erythropoiesis tissues. In addition,
in peripheral blood of these mice we found abnormally premature erythroid cells containing
calnexin that is normally completely lost before reticulocytes are released into the circulation.
In conclusion, our data suggest that the absence of integrin β3 impairs adhesion of the
erythroid at the latest developmental stage to the central macrophage of erythropoietic islands
resulting in preterm release of abnormally immature erythrocytes into the circulation.
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ZUSAMMENFASSUNG
Sowohl während der normalen als auch der stimulierten Blutbildung (Erythropoiese)
differenzieren die Erythroblasten in direktem Kontakt mit einem zentralen Makrophagen.
Diese mikroanatomische Struktur wird erythroblastische Insel genannt. Bishereige
Forschungdaten zeigen, dass die Zellkontakte nicht nur zwischen Erythroblasten und dem
zentralen Makrophagen sondern auch die Kontakte zwischen den Erythroblasten innerhalb der
erythroblastischen Inseln entscheidend für die korrekte Reifung der Erythrozyten ist.
Die Stabilität der erythroblastischen Inseln wird durch eine Vielzahl von
Adhäsionsmolekülen vermittelt, welche im Wesentlichen der Integrin-Proteinfamilie
zuzuordnen sind. Zentral scheint hier das Landsteiner-Weiner Blutgruppen Glykoprotein
intercellular adhesion molecule-4 (ICAM-4) zu sein, das die Integrinheterodimere αLβ2,
αMβ2, αIIbβ3, αvβ1, αvβ5 and αvβ3 binden kann. Von diesen ist wohl αv essentiell für die
Bildung und Stabilisierung der erythroblastischen Inseln durch direkte Interaktion mit
ICAM-4. Allerdings ist bisher unbekannt, welches β-Integrin der Heterodimerisationspartner
von αv in dieser Struktur ist.
Durch Vergleich der Stresserythropoiese in Mäusen, denen das β3-Integrin fehlt mit
Mäusen, die Erythropoietin konstant überexprimieren konnte eine Rolle β3-Integrin für die
Stabilisierung von erythroblastischen Inseln gefunden werden. Mäuse ohne β3-Integrin hatten
eine reduzierte Anzahl von Erythroblasten pro Insel und einen reduzierten Anteil der Zellen
der spätesten Erythrozytenentwicklungsstadien im Knochenmark. Zudem enthielten diese
Mäuse im peripheren Blut abnorm unreife Erythrozyten, da diese Calnexin enthielten, ein
Protein, das normalerweise vollständig aus den Erythozyten verschwindet, bevor sie in den
Kreislauf gelangen. Somit legen unsere Daten nahe, dass das Fehlen von β3-Integrin die
Haftung der späten Erythrozytenentwicklungstadien an den zentralen Makrophagen stört, was
zu einer Freisetzung von abnorm unreifen Zellen in die periphere Zirkulation führt.
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LIST OF ABBREVIATIONS
BFU-E burst forming unit erythroid
CFU-E colony forming unit erythroid
CSF colony stimulating factor
DMT1 divalent metal transporter 1
EI erythroblastic island
EMP erythroblast macrophage protein
EPO erythropoietin
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GAS6 growth arrest specific gene 6
HIF hypoxia inducible factor
HOX-1 heme oxygenase-1
HRE hypoxia-response element
HSCs hematopoietic stem cells
ICAM-4 erythroid intercellular adhesion molecule-4
IgG immunoglobulin G
IRE iron responsive element
IRP IRE/iron regulatory protein
JAK2 Janus kinase 2
MAPK mitogen-activated protein kinase
PHD prolyl hydroxylase domain
PIGF placenta growth factor
RB retinoblastoma protein
RBCs red blood cells
RCAS receptor binding cancer antigen expressed in SiSo cell
SCF stem cell factor
SIRPα signal regulatory protein α
TNF tumor necrosis factor
VCAM-1 vascular cell adhesion molecule-1
VEGF vascula endothelial growth factor
VHL Von Hippel-Lindau tumor suppressor protein
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CHAPTER 1. INTRODUCTION
1.1. ERYTHROPOIESIS
Erythropoiesis is necessary for large multicellular organisms such as mammals to
ensure oxygen transport to all cells. Primitive hematopoiesis occurs in the yolk sac/blood
islands, later at the aorta-gonad mesonephros region, the chorio-allantoic placenta, and
releases nucleated red blood cells (RBCs) into the circulation. Nuclei gradually condense
before being extruded. Definitive erythropoiesis begins in fetal liver and finally shifts from
the fetal liver to the bone marrow to produce enucleated RBCs (figure 1) (1). In addition,
stress erythropoiesis can be induced in adult mice in the spleen to generate more red cells
(2,3,4,5).
Figure 1. In mammalian embryonic development, primitive erythropoietic progenitors
differentiated from hemangioblasts originated from yolk sac. These cells mature in the
bloodstream and develop into enucleated reticulocytes. At later stage of fetal development, a
population of transient embryonic burst forming unit erythroid (BFU-E) emerges from the
yolk sac and later seeds in the fetal liver. There they enucleate to become the first definitive
RBCs of fetus. Eventually, in the late gestation liver and postnatal bone marrow definitive
erythroid progenitors originated from hematopoietic stem cells. There these erythroid
precursors mature within erythroblast islands. μФ: macrophage cells (1).
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1.1.1. Primitive erythropoiesis
The formation of mesoderm cells initiates the generation of erythroid cells in the
embryo of mammal. These mesoderm cells possess a pluripotent nature and can differentiate
into both erythropoietic cells, epithelial cells and other mesenchyme-derived tissues
(12,13,14). In the yolk sac, mesoderm cells committed to primitive erythropoietic cells pool
into so-called blood islands (6,7). Each blood island contains a central core consists of
erythropoietic progenitors surrounded by a rim of outer endothelial cells, which later form the
initial vascular plexus of the yolk sac (8,9). The close spatial and temporal appearance of
primitive erythropoietic cells and endothelial cells had suggested that these lineages share a
common origin, which were later identified and termed hemangioblasts (10,11). In adult
erythropoiesis, nuclear transcription factor GATA-2 is crucial for the survival and
proliferation of hematopoietic stem cells (HSCs) (15,16). However, GATA-1 promotes
specifically the survival of erythroid precursors through inducing Bcl-xL expression (17,18).
GATA-1, GATA-2 have been shown to regulate hemangioblast precursors as well (19,20).
Nucleated primitive erythroblasts in the blood islands begin to circulate in the cardiovascular
system starting at E8.25 in mice (21,22,23). Over the next 8 days, primitive erythroid cells
undergo cell divisions, hemoglobin accumulation, decrease in cell size, nuclear condensation
and ultimately loss of euchromatin (24,25).
The primitive erythroblast enucleation results in a transient appearance of a population
of very small, globin containing, nucleated cells in the circulation of mouse embryos. These
cells are reminiscent of extruded nuclei, termed pyrenocytes (26,27). The discovery of
primitive pyrenocytes in the fetal bloodstream suggests that late-stage primitive erythroblasts
enucleate in the circulation. However, primitive erythroblasts do not enucleate spontaneously
when cultured (26). Interestingly, they are capable of physically interacting with
F4/80-positive macrophage cells in vitro. These interactions are mediated in part through
α4β1 integrins present on primitive erythroid cells and vascular cell adhesion molecule-1
(VCAM-1) expressed by fetal liver macrophage. Taking together, these observations raise the
possibility that primitive erythroid cells enucleate while associated with macrophage cells in
vivo (26,27).
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1.1.2. Definitive erythropoiesis
At later stages of mammalian fetal development, more red blood cells are needed to
meet the demand for growth. Prior to the formation of bone marrow, fetal liver serves as the
site of definitive erythropoiesis. External erythropoietic elements such as BFU-Es from the
yolk sac invade the fetal liver soon after it begins to form as an organ. BFU-Es proliferate and
differentiate into colony forming unit erythroids (CFU-Es), which subsequently expand
exponentially in numbers and generate definitive erythroid cells (28,29).
In mammalian embryo, definitive erythropoiesis moves from the fetal liver to the newly
formed bone marrow towards the end of gestation. Postnatal definitive erythropoiesis is a
continuous process of proliferation and differentiation starting with bone marrow HSCs and
resulting in anucleate erythrocytes (Figure 2) (33,34). In the adult bone marrow, HSCs present
less than 0.01% of the nucleated cells in the bone marrow and possess the capacities to
self-renew and differentiate into all cells of the blood and immune system. The earliest stage
of progenitor cell differentiation that is committed to the erythroid lineage is BFU-E which
could develop into more mature CFU-E, both have been identified by in vitro colony-forming
assays. Although fundamentally similar, adult and fetal erythroid progenitors differ with some
distinctive features. First, fetal hepatic BFU-Es proliferate more rapidly than their adult
counterpart. Second, fetal liver BFU-Es, in contrast to adult bone marrow BFU-Es, are
capable of proliferating in response to erythropoietin (EPO) in the absence of added
colony-stimulating factor (CSF) or interleukin-3 (30,31). Lastly, CFU-Es in the murine fetus
are more sensitive to EPO (32).
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Figure 2. Erythroblasts differentiation stages from dividing self-renewing HSCs through the
mature erythrocytes (adapted from https://commons.wikimedia.org/wiki/File: Hematopoiesis
_(human)_diagram.png).
In definitive erythropoiesis, CFU-E gives rise to proerythroblast, basophilic,
polychromatic and orthochromatic erythroblast. They are morphologically distinct and could
be identified by means of cell-surface markers (35,36). During the process of maturation,
erythroblasts gradually lose all the organelles before fully matured. In contrast to primitive
erythroid cells that enucleate in the blood stream, the definitive erythroid precursors in the
fetal liver and postnatal bone marrow enucleate in the erythroblastic islands (EI). The
extruded nuclei are surrounded by a rim of plasma membrane of definitive erythroid cells and
undergo rapid loss of the phosphatidylserine asymmetry of the cell membrane, which leads to
recognition and engulfment by the associated macrophage cells (37,38,39,40). Therefore,
erythrocytes in the circulation are devoid of nucleus and internal organelles (37).
1.1.2.1. Erythropoiesis niche: EI
Proliferation and differentiation of erythroblasts occur within the microenvironment EI
(Figure 3). The first description of this erythropoietic unit dates back to the 1950's when
French hematologist Marcel Bessis identified it. Based on transmission electron microscopic
analysis of bone marrow sections, Bessis characterized EI as developing erythroblasts
surrounding a central macrophage (41). Originally assumed by Bessis, the central macrophage
serves as a "nursing" cell, supplying nutrients and growth factors to the developing
erythroblasts and phagocytose extruded nuclear (42).
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EI exists in hematopoietic organs such as fetal liver as well as bone marrow. In normal
erythropoiesis, the EI is composed of a central macrophage surrounded by erythroblast at
different stages of erythropoiesis from nucleated proerythroblasts through multilobulated
reticulocytes (43). In mice, the central macrophage can be distinguished from the
heterogeneous population of monocytes and macrophages as well as other stromal cells by
expression of F4/80 antigen and Forssman glycosphingolipid. In the bone marrow, EIs are
found with equal distribution adjacent and non-adjacent to the sinusoid. Of note, the islands
more distant to the sinusoids contain more proerythroblasts while islands neighboring
sinusoids have more differentiated erythroblasts (44,45).
A diverse array of adhesion molecules mediates both erythroblast/erythroblast and
erythroblast/macrophage interactions (Figure 3). Erythroblast macrophage protein (EMP) was
the first molecule identified to be involved in the attachment of macrophage/erythroblast and
erythroblast/erythroblast through homophilic binding. EMP is a transmembrane protein with a
molecular weight of 36-kDa and expressed by both macrophage and erythroblasts (46). In
vitro, when EMP-mediated interaction of erythroblasts with central macrophage was blocked
by antibodies, erythroid cells matured to the late erythroblast stage but failed to enucleate and
underwent apoptosis (47). In vivo, fetuses with deficient of EMP became severely anemic and
then die in uterus, which provides further evidence on the important role of EMP in
erythropoiesis (48). Subsequently another set of receptor/countereceptor, α4β1 integrin in
erythroblasts and VCAM-1 in central macrophages was found to contribute to the
erythroblast/macrophage interactions within the islands. Most recently, the interaction of
erythroid intercellular adhesion molecule-4 (ICAM-4) and macrophage αv integrin has been
identified to participate in island formation (49,50,51). The yet unanswered question is the
role of this adhesive molecular attachment. It is speculated that these receptor-counterreceptor
interactions may trigger signaling pathways coordinating adhesion and timely release of the
reticulocytes and gene expression (37).
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Figure 3. Erythroblasts extrude their nucleus within the niche. Expelled nuclei are
phagocytosed by the central macrophage. An array of adhesion molecules is involved in the
attachment of the macrophage with erythroblasts, including homophilic interaction of EMP,
VCAM-1 with integrin α4β1 and ICAM-4 with integrin αv (54).
As described by Bessis and other researchers, one of the key functions of the central
macrophage is to engulf nuclei extruded during the terminal RBC differentiation (52,53). The
extruded nucleus is surrounded by plasma membrane separated from erythroblast cytoplasm.
It has been reported that during enucleation, the erythroblast plasma membrane components
were sorted to the plasma membranes of the nascent reticulocyte and/or the expelled nucleus.
In this process, the erythroblast membrane protein EMP and β1 integrin predominantly
remain on the extruded nuclei and enable their attachment to the macrophage surface (54,55).
Evidence from in vitro co-culture of erythroblasts and macrophages indicated that nuclei
expelled from fetal liver erythroblasts expose phosphatidylserine on their surface that is
recognized subsequently by macrophages, resulting in phagocytosis and degradation by
DNase II within the central macrophage (38,56).
Furthermore, Bessis proposed an important role of macrophage in the transfer of iron to
adherent erythroblasts (42). Indeed using co-culture it was shown that macrophages
synthesize and secrete ferritin under transferrin free conditions. Iron released from this ferritin
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was used by erythroblasts for heme synthesis (57). However, this idea remains controversial
and other research groups found evidence indicating that central macrophages are irrelevant
for delivering of iron to erythroblasts (37).
Perturbations in macrophage function affect red cell production and result in anemia.
There is evidence indicating that the retinoblastoma protein (RB) mediates this process
through regulating the maturation of macrophages. RB is a nuclear protein with ubiquitous
expression and is essential to the cell's decision to transverse the cell cycle. Mice lacking RB
have deficiencies in the nervous system, placenta, eye lens as well as in erythropoiesis. The
most recent evidence revealed that RB-deficient fetuses fail to form functional erythroid
islands due to the severe defects in the macrophage lineage (58,59). However, the role of RB
might be much more complex as a number of recent findings from in vivo investigations
suggested that anemia in RB-null mice may involve also to erythroblast defects (60,61).
Despite the fact that progress is made in elucidating the role of the central macrophage
in regulating erythropoiesis, little is known concerning the molecular mechanisms through
which macrophages enhance erythroid proliferation and how regulatory factors operating in
the EI to regulate erythropoiesis (54).
1.1.2.1.1. Regulatory factors within EI
During terminal differentiation, the adhesive proteins of the erythroblast membrane
appear to be lost gradually. This implies that the cell-cell adhesive interactions are involved in
the erythroblast differentiation. Growing evidence are demonstrating the crucial role of both
macrophage/erythroblast and erythroblast/erythroblast interaction within EI during
erythropoiesis (60). It has been speculated that erythroblast development is regulated through
a balance between positive and negative feedback mechanisms. Cell-cell interactions and
soluble factors are regulators in this process (54).
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1.1.2.1.1.1. Cell-cell interactions
Macrophage interaction with erythroblasts
In vitro co-culture of macrophages and erythroblasts in the presence of physiological
concentrations of EPO indicates that direct contact with macrophage enhances the
proliferation of erythroblasts. Cell cycle analysis showed that the improved erythroblast
proliferation resulted from a decreased transit time in the G0/G1 phase. More cell divisions
were completed during a limited period and consequently more reticulocytes were generated
(46,63,64,65). The candidate proteins identified to govern these changes in cell-cycle
dynamics are the macrophage membrane protein Ephrin-2 (HTK ligand) and its receptor
EphB4 (HTK) expressed by CFU-E (66,67,68).
The negative mechanism existing between cellular components of the EI involves
receptor binding cancer antigen expressed in SiSo cells (RCAS) and its receptor. RCAS1 is
secreted by bone marrow macrophages and immature erythroblasts express RCAS1 receptor.
The binding of RCAS1 to the RCAS1 receptor activates proapoptotic caspases 8 and 3,
leading to apoptotic death in immature erythroblasts (69).
Interaction between erythroblasts
In a study of erythroblast terminal differentiation, Fas/Fas ligand interaction was found
to regulate survival of erythroblasts. Erythroblasts express Fas throughout terminal
differentiation. Crosslinking of Fas/FasL transduces apoptotic death signal to the immature
early stage erythroblasts, but mature erythroblasts remained unaffected. At the end of
maturation, FasL was induced in orthochromatic erythroblasts, which demonstrates a Fas
based cytotoxicity against less mature early erythroblasts within EI (70). EPO counteracts
erythroblast apoptosis initiated by Fas ligation, thus provides protection to early erythroblasts
(71).
It has long been recognized that the level of transcription factor GATA-1 is crucial for
completion of normal erythroblast differentiation. Absence of GATA-1 expression is
embryonically lethal and results in proerythroblast apoptosis (72,73,74,75), whereas, GATA-1
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overexpressing erythroblasts are unable to complete terminal differentiation (76,77). However,
co-culture of wild-type with GATA-1 overexpressing erythroblasts rescued the GATA-1
overexpressing erythroblasts to complete terminal differentiation. It was proposed that a
signal generated by wild-type cells overcomes the intrinsic defect in GATA1-overexpressing
erythroid cells. This pinpoints the importance of homotypic signaling between erythroblasts
within EI niches as a mechanism for regulating GATA-1 activity (78).
1.1.2.1.1.2. Soluble factors
Macrophages within EI secrete macrophage cytokines, including burst promoting
activity and insulin-like growth factor, inducing growth of both BFU-Es and CFU-Es
(79,80,81). Erythroblasts also secrete soluble factors. A very recent discovery is that
erythroblasts release growth arrest specific gene 6 (GAS6) in response to EPO. GAS6 could
bind to its receptor also located on erythroblasts, this way activates phosphoinositide 3 kinase
and its effector AKT to enforce EPO receptor signaling, thus enhancing proliferation and
survival of erythroid cells. Moreover, binding of GAS6 to macrophages decreases
macrophage secretion of erythroid inhibitory factors (82). Differentiating erythroblasts also
secrete angiogenic factors, vascular endothelial growth factor A (VEGF-A) and placenta
growth factor (PIGF). The absence of VEGF-A and PIGF receptors on erythrocytes suggests
that these secreted angiogenic factors may serve as paracrine effectors, mediating crosstalk
between receptor-expressing macrophages and developing erythroblasts and may regulate
island structure and/or localization (83).
In inflammation and malignancy, elevated cytokines secreted by central macrophage
such as tumor necrosis factor (TNF), Interleukin-6 and interferon-γ appear to inhibit EPO
signaling and promoting cell death of erythroblasts. TNF-α could induce apoptosis or retard
proliferation (84). TNF-β may reduce the number of progenitor cells by blocking proliferation
and accelerating differentiation of erythroid progenitors (85). Interleukin-6 was found to
prevent iron release from central macrophage thus blocking the supply of iron for
erythropoiesis (86). Elevated interferon-γ was shown to upregulate in both macrophages and
erythroblasts the expression and secretion of TNF-related apoptosis inducing ligand, which
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inhibits differentiation of erythroblasts through activating p42/44 mitogen-activated protein
kinase (MAPK) pathway (87).
1.1.2.2. Extracellular matrix: role of fibronectin and laminin
Interactions of receptors found on erythroblasts with extracellular matrix components,
such as fibronectin and laminin, affect erythropoiesis by influencing terminal differentiation
and migration of erythroid cells (88). It seems that the proliferation of erythroblasts is
regulated by an EPO-dependent phase followed by an integrin/fibronectin dependent phase
(88). Erythroblasts express fibronectin receptors α4β1 and α5β1. The expression of α5β1
gradually decreases during terminal differentiation that leaves α4β1 the sole fibronectin
receptor on the late stage erythroblasts (89). The progressive loss of adherence to fibronectin
facilitates the release of reticulocytes at the late stage of differentiation (90).
Various laminins localize to different regions in the bone marrow extracellular matrix.
Among them, laminins10/11 presents in the subendothelial basement membrane of bone
marrow sinusoids (91). As a receptor of laminin, Lutheran, which is present on the late stage
erythroblasts, has a specific, high-affinity for laminins10/11 (92,93,94,95). It is speculated
that the interaction between Lutheran and laminin may facilitate the movement of reticulocyte
to sinusoids and subsequent egress into circulation (54).
1.1.2.3. Loss of organelles during terminal erythroblast differentiation
During development, erythroblasts progressively lose RNA, accumulate more
hemoglobin and condense chromatin. The nucleus is finally extruded and exposes
phosphatidylserine on its surface, which triggers phagocytosis by the central macrophage (38).
In the circulation, some remnant of organelles, such as mitochondria, endocytic vesicles,
ribosomes, Golgi cisternae and rough endoplasmic are retained within reticulocytes. During
the process of maturation into erythrocytes, reticulocytes lose all the organelles (39,40). How
the organelles are removed remains to be described. By using knockout mouse models, it was
demonstrated that Nix, a BH3-only protein, plays a critical role in the mitochondrial
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degradation in reticulocytes. Lack of this protein arrests terminal erythroid differentiation
through inhibiting mitochondrial incorporation into autophagosomes and autophagosome
maturation, resulting in an erythroid maturation defect (96,97,98). In contrast to Nix, Bim and
PUMA, two other BH3-only proteins of the Bcl-2 family are not required for mitochondrial
clearance in reticulocytes (97). In addition, ULK1, a ubiquitously expressed serine-threonine
kinase, has been suggested to be involved in the organelle clearance (99). Autophagic activity
was also found to be in the mechanism of exosome formation, finally reducing cell surface
area and cell volume during maturation into erythrocytes. However, little is known about
molecular mechanisms responsible for this process (100,101).
1.1.3. Hemoglobin switching and regulation
Primitive erythroid cells express ζ-globin, βH1-globin, and εγ-globin in addition to
α1-globin, α2-globin, β1-globin and β2-globin, which are expressed in definitive erythroid
cells in the mouse. During erythropoiesis, the expression of globin chains varies with the
maturation stage in the primitive and definitive RBCs (102). Moreover, the hemoglobin
content of primitive RBC was found to be a few times the amount in definitive erythrocytes
(103). Gene expression analysis in primitive erythroid cells of early erythropoietic stages
indicates that the initial expression of ζ-globin, βH1-globin genes is later switched to the
α1-globin, α2-globin and εγ-globin genes, respectively, during the maturation process of
primitive proerythroblasts to reticulocytes (104). Consequently, primitive RBCs express
increasing levels of adult globins as gestation progresses, whereas definitive RBCs harbor
only the adult protein variants (105). Some transcription factors are found to be essential in
regulating the expression of globin in both primitive and definitive erythropoiesis. For
example, the erythroid-specific kruppel like factor initially identified to regulate the adult
β-globin genes was found to also play a role in the controlling of multiple erythroid-specific
genes, including α-globin stabilizing protein and heme synthesis pathway proteins in the
primitive erythropoieses as well (107,108). The deficiency of KLF2, a Kruppel-like transcript
factor, has been found to decrease βH1-globin and εγ-globin expression level (106).
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1.2. KEY FACTORS AFFECTING ERYTHROPOIESIS
Physiologically, the availability of nutritional factors, as well as status such as hypoxia
represent key elements contributing to erythropoiesis. Although many questions still remain
unanswered regarding the underlying molecular mechanisms that govern lineage-determining
decisions toward the path of terminal maturation, specific signaling pathways and molecular
networks have been identified to strictly regulate cell proliferation, prevent apoptosis, and
coordinate cell-cycle arrest within terminal maturation (109).
1.2.1. Nutritional factors
1.2.1.1. Folate and vitamin B12
Folate is present in both plant and animal tissues in the form of 5-methyl-THF
(tetrahydrofolate, a reduced form of folate). In animals, 5-methyl-THF is absorbed in the
jejunum after enzymatic cleavage to the monoglutamic form. Thus, in the circulation, folate is
present as 5-methyl-TNF monoglutamate. Once folate is transported into cells, the
folylpolyglutamate synthetase converts folate to the polyglutamyl form (110,111). Vitamin
B12 is produced by microorganisms in the mammalian gut and was found to circulate as
vitamin B12-transcobalamin II complex, a functional carrier of vitamin B12 to the cells. As a
coenzyme, it is involved in the transfer of a methyl group from 5-methyl-THF to
homocysterin, thereby regenerating methionine. Thus a metabolic link exists between folate
and vitamin B12 (112).
The deficiency of either folate or vitamin B12 cause megaloblastic anemia, characterized
by pancytopenia with macrocytic erythrocytes, hypersegmented neutrophilic granulocytes and
reticulocytopenia. Although affecting all hematopoietic lineages, megaloblastic anemia is
most prominent in the erythroid lineage with an increased death rate of premature cells in the
bone marrow, which leads to the appearance of increased numbers of large immature
erythroblasts. Impaired DNA synthesis and its sequelae are key elements in the increased cell
death that characterize this anemia. Impaired DNA synthesis would be expected to result in
chromosomal breakage and possibly nuclear damage as indeed had been shown in the bone
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marrow cells of patients with folate or vitamin B12 deficiency (113,114,115). The underlying
mechanism is that folate or vitamin B12 deficiency decreases de novo synthesis of
deoxynucleotides which in turn results in impaired synthesis and repair of DNA, and
ultimately, in cell death (115,116,117).
In vivo and in vitro evidences document the morphological changes of ineffective
erythropoiesis caused by folate or vitamin B12 deficiency. In vitro, the majority of
erythroblasts undergo apoptosis in S-phase when cultured under folate-deficient conditions.
The folate-deficient erythroid cells can be rescued from cell death by supplied in the medium
containing sufficient amounts of both thymidine and purines or purine nucleosides to provide
the necessary deoxynucleotides that permit DNA synthesis (118). In vivo, mice fed with
folate- deficient diet develop a macrocytic anemia with decreased reticulocytes (119,120). As
the folate-deficiency anemia progresses, the total number of nucleated cells decreases in the
bone marrow erythroid cell population. In parallel, the size of the individual cells increases
and cells undergo apoptosis. Although the absolute numbers of reticulocytes are decreased in
folate-deficient mice, the absolute numbers of CFU-Es are increased in their bone marrow and
spleen (119). It was postulated in folate-deficient mice, that EPO levels are elevated as a
response to the anemia. More EPO responsive erythroid cells at early differentiation stages
survive in an EPO-dependent manner. However, most of these early state erythroid cells fail
to persist in the subsequent stages of differentiation, most often succumb to apoptosis while in
S-phase of the cell cycle (120).
1.2.1.2. Iron
Iron is an essential component of many different proteins with vital function. Restriction
of iron delivery to erythrocyte precursors limits erythropoiesis since most of the iron is used
for the synthesis of hemoglobin in erythroid cells. Cellular iron acquisition and transportation
depends on an array of proteins, among which, transferrin, transferrin receptor, and ferritin
were considered to be the key players in iron metabolism (121).
Both heme-bound and elemental iron is absorbed through the brush border of the upper
small intestine (122). Inorganic iron is first reduced from the oxidized form before being
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absorbed by duodenal enterocytes via the divalent metal transporter1 (DMT1/SLC11A2)
(123). Heme iron is absorbed by an unknown mechanism (124). Intracellularly, heme iron is
released by inducible hemoxygenase 1 (HOX-1) (125). Cytosolic iron is then exported by
ferroportin with the ferroxidase activity of hephaestin, facilitating the movement of iron
across the enterocyte membrane to the circulation (126,127).
Physiologically, the iron absorption is affected by iron storage and rate of utilization
(122). The 3`UTR of mRNA of DMT1 expressed in intestinal cells contains the iron
responsive element (IRE). IREs are nucleotide sequences that is recognized by cytosolic
IRE/iron regulatory proteins, known as IRP1 and IRP2. Diminished iron levels would result
in the binding of IRP2 to IREs in 3`UTR and stabilizes the transcript, which leads to an
increased DMT1 expression and subsequently iron absorption (128,129). Additionally,
through an unknown mechanism, hypoxia can stimulate iron absorption independent of
erythropoietic activity (130).
Iron is transported within the body in the form of plasma transferrin because under
physiological conditions, iron exists as Fe3+, which is virtually insoluble at neutral pH.
Transferrin is a glycoprotein that binds Fe3+ very tightly but reversely. Most of the iron is
used for the synthesis of hemoglobin in erythroid cells (131). Therefore, physiologically,
erythroid precursors take up iron from transferrin. Delivery of iron to cells occurs after
binding of transferrin to its receptors on the cell membrane (132,133). Upon entering cells,
Fe3+ is released from transferrin by a process involving endosomal acidification. In erythroid
cells, reduction of Fe3+ to Fe2+ occurs in the endosome, and then irons targets toward
intracellular sites of use or storage in ferritin. Mitochondria are the main site of heme
production by ferrochelatase, the enzyme that inserts Fe2+ into protoporphyrin IX (134).
Within erythroid cells, iron moves between various intracellular compartments. The
intracellular iron is tightly controlled through regulating transferrin receptor and iron storage
protein ferritin. The increase of cellular iron concentration stimulates ferritin synthesis and
prevents the expression of transferrin receptor and vice versa. Iron dependent regulation of
ferritin and transferrin receptors occurs post-transcriptionally. mRNAs of both proteins
possess IREs. In ferritin, IREs are located in the 5` UTRs of the mRNA whereas similar IREs
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are present in the 3`UTR of the transferring receptor mRNA. Binding of IRP1 to IREs in the
5`end of mRNA inhibits its translation. In contrast, binding of IRP2 to IREs in 3`UTR
stabilizes the transcript. Iron storage expansion inactivates IRP1 and promotes degradation of
IRP2, leading to increased ferritin levels and degradation of transferrin receptor mRNA. Visa
versa, iron deficiency promotes cellular iron acquisition and decreases the cellular
iron-storing protein (135).
Recycled hemoglobin iron by macrophage is the most important source of iron for daily
erythropoiesis. In this process, senescent erythrocytes are phagocytosed by macrophages of
the reticuloendothelial system where the heme moiety is split from hemoglobin and
catabolized enzymatically via HOX-1. Thereafter, iron is freed from the protoporphyrin ring
and exported by ferroportin to rejoin circulation (131).
The iron deficiency anemia results from insufficient supply of iron for heme synthesis
and, consequently, hemoglobin formation in developing erythroid cells. Erythrocytes appear
smaller than normal (microcytic) and contain reduced amounts of hemoglobin (hypochromic).
The prevalence of anemia caused by iron deficiency is about a billion people worldwide.
Patients with chronic disease such as infectious, inflammatory, or neoplastic disorders suffer
from anemia caused by iron-deficient erythropoiesis and resultant defect in the recycling of
hemoglobin iron in the reticuloendothelial system (136).
1.2.2. Erythropoietic cytokine: EPO
The production of hematopoietic cells is tightly regulated by hematopoietic cytokine
superfamily. Each cytokine has multiple actions controlling the survival, proliferation,
differentiation and maturation of the hematopoietic cells. HSCs and early progenitors possess
the receptor c-kit of a stem cell factor (SCF), which is a powerful stimulus for the
proliferation of these cells (137,138). During hematopoiesis, CSF is needed to stimulate
granulocyte and macrophage colony formation (139,140,141,142,143). Interleukin-5 is a
major regulator of eosinophil production (144). Leukemia inhibitory factor was found to
stimulate the megakaryocyte colony formation (145). Interleukin-11 was proved to stimulate
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megakaryocytopoiesis (146). Thrombopoietin strongly induces the megakaryocyte colony
formation (147).
As a member of the hematopoietic cytokine superfamily, EPO is known as the
predominant regulator of erythropoiesis. EPO is a glycoprotein with a molecular weight of
34-kDa and was first identified as a humoral erythropoietic factor in the 1950's (148,149).
This glycoprotein hormone is produced mainly in the fetal liver hepatocytes and a subset of
peritubular, interstitial cells in the adult renal cortex. Additionally, early-stage erythroid
progenitors and neural cells were also found to express EPO (150,151,152,153). Under
normal circumstances, only a few of interstitial cells produce EPO. Conditions that need to
increase oxygen delivery, such as the residence at high altitude, pulmonary disease that results
in decreased uptake of oxygen, admixture of venous to arterial blood through a right to left
shunt and decreased renal blood flow stimulate EPO production. The number of interstitial
cells that produce EPO increases exponentially in response to low oxygen tension (154,155).
Conversely, inflammatory cytokines decrease EPO production. This is the primary cause of
anemia of chronic inflammatory disease and the anemia of cancer (156,157).
1.2.2.1. Regulation of EPO production by HIF
The EPO gene is predominantly regulated by hypoxia-inducible factor (HIF) family
(158,159). HIF was first identified as heterodimer consisting of an oxygen labile α-subunit
and a constitutive β-subunit. All HIF-subunits are members of the Per-ARNT-Sim family of
proteins (160,161). HIF-1α has a ubiquitous expression in tissues, whereas HIF-2α is
restricted to certain cells types. Little is known about HIF-3α. All isoforms of HIF-α can form
heterodimers with the β-subunit of HIF(162,163).
HIF was identified to target genes such as EPO that is essential for the hypoxic response
through acting as a transcriptional activator (164,165). Under hypoxic conditions, HIF-2
stimulates the expression of EPO through binding to the hypoxia-response element enhancer
region of the EPO gene promotor (166,167,168). Many more target genes of HIF have been
subsequently found such as VEGF, glucose uptake transporter-1, transferrin, transferrin
receptor, plasminogen activator inhibitor-1, aldolase C, and endothelin (169).
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In accordance with the effects of hypoxia on serum EPO, the DNA-binding activity of
HIF-α was found to be tightly regulated by cellular oxygen tension. Primary regulator of HIF
stability is prolyl hydroxylase domain (PHD) enzymes that initiate the degradation of HIF via
the von Hippel-Lindau tumor suppressor protein (VHL), a protein with ubiquitous expression.
VHL is acting as the recognition component of a multiprotein ubiquitin ligase complex.
Site-specific prolyl hydroxylation of HIF-α allows VHL binding and targeting for
ubiquitin-mediated proteasomal degradation. This process is considered as the fundamental
oxygen-sensitive step underlying the degradation of HIF-α. Thus, prolyl hydroxylation is the
key element regulating the oxygen-sensitive turnover of HIF-α (170).
A family of three prolyl hydroxylases, PHD1, PHD2 and PHD3 has been identified. The
isoforms of PHD have the tissue-specific expression. PHD1 is particularly expressed in testis.
PHD2 could be found in more tissues and PHD3 is expressed at high levels in heart and
skeletal muscle (171,172). Moreover, PHD2 and PHD3 are more cytoplasmic, whereas PHD1
is generally confined to nuclei (173,174). PHDs were also found to be regulated by HIF-α
activity during hypoxia because the genes of PHD2 and PHD3 are targeted by HIF following
hypoxic stimulation. Thus, a putative feedback loop also exits in HIF regulation (175,176).
1.2.2.2. EPO/EPOR signaling
The receptor of EPO, EPOR, is expressed in erythroid progenitors but also by a number
of other tissues including cardiovascular system, kidney, placenta, macrophage, retinal cells
and brain (171). The EPOR expression is stimulated by SCF , interleukin-1α and inhibited by
interferon-1γ, ionomycin and phorbol ester phorbol-12-myristate-13-acetate (172,177,178).
In erythropoietic cells, EPOR starts to appear on late CFU-Es and proerythroblasts
(179). In the bone marrow, EPO acts upon erythroid progenitors in the stages from CFU-E to
the earliest basophilic erythroblasts. These cells are EPO responsive cells. Progenitor cells at
these stages are dependent on widely varying amounts of EPO to promote proliferation,
differentiation, and survival of erythroid precursors (180,181,182). Upon EPO binding to its
receptor, the receptor undergoes a conformational change that activates a prebound,
cytoplasmic, tyrosine kinase, Janus kinase 2 (JAK2) (183,184,185,186,187). Subsequently,
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JAK2 phosphorylates several cytoplasmic tyrosine residues in the cytoplasmic tail of the
EPOR that act as docking sites for proteins that contain Src-homology 2 domains.
Consequently, multiple pathways mediating the cell proliferation and survival are activated,
including signal transducer and activator of transcription 5, PI-3K/AKT, and MAPK
(186,187).
Abnormal signaling pathways of the EPO-receptor occur for human erythropoietic
disorders (188,189). For example, the prototypical erythropoietic disease, polycythemia vera
is caused by various mutations of JAK2 (190,191,192) or Bcl-xL expression, which result in
EPO-independent erythroblast growth (193,194,195,196).
1.3. STRESS ERYTHROPOIESIS
During normal erythropoiesis, as seen in healthy subject at sea level, the production of
red cells equals the removal of senescent erythrocytes. In response to certain physiological or
pathological stimuli, the red cell production increases dramatically, a process named stress
erythropoiesis. Stress erythropoiesis is essential to adapt the mammalian organism to
conditions resulting in low tissue oxygen tension, including cardiac or pulmonary diseases,
blood loss, etc. In mice, stress erythropoiesis occurs in adult spleen and liver and during fetal
development in the fetal liver. Growing evidence has suggests that stress erythropoiesis is
more than a process simply enhancing steady-state erythropoiesis but a process requiring
distinct quantitative and qualitative changes of cytokine pattern to stimulate erythropoiesis
from unique progenitor cells (197,198,199,200).
Conditions of reduced arterial oxygen content (hypoxia) result in increased EPO plasma
levels as a consequence of stimulated synthesis and secretion from kidney cells. In parallel,
EPOR expression is found on a broader progenitor spectrum as compared to basal
erythropoiesis, enabling EPO to exert its effect also on early hematopoietic progenitors, such
as HSCs additionally to the EPOR expression in steady status that is restricted to progenitors
such as CFU-Es. Moreover, bone marrow progenitors migrate to the spleen and subsequently
differentiate into stress BFU-E under the influence of Hedgehog signaling and bone
morphogenetic protein 4 (201). Consequently, erythropoiesis is enhanced by 10-100 fold
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increase in the number of BFU-E and CFU-E in mouse spleen (202,203,204,205). In contrast
to bone marrow BFU-Es, cultured spleen BFU-Es have been identified to produce erythroid
colonies when exposed to high EPO concentration without addition of SCF or interleukin-3
(206).
The link between steady-state erythropoiesis and stress erythropoiesis remains variable.
The deficiency of GAS6 or conditional deletion of focal adhesion kinase has affected stress
erythropoiesis rather than homeostasis (82,207,208). On the other hand, stress erythropoiesis
in the splenic microenvironment can be successful in the mice with a deficiency of Rac1 and
Rac2 GTPases although these mice suffer from pathologic erythropoiesis under steady state
conditions (208).
1.4. SENESCENCE AND CLEARANCE OF RBC
Matured mammalian RBCs circulate as anucleate biconcave cell with concentrated
hemoglobin solution packed within protein-stabilized lipid bilayers. In the circulation, RBC
life span varies with species and little is known about what factors determine the inter species
RBC life span. A consensus exists that the life and death of RBCs are well regulated despite
their lack of ability for protein synthesis (209).
Experimental evidence suggests that there are various mechanisms underlying the
senescence of RBCs. The life span of erythrocytes is influenced by many factors such as
metabolic rate, oxidative stress etc. Oxidative damage is likely to be one of the most
important cause of RBC senescence and the exposure of senescence-associated ligands
phosphatidylserine on the RBC surface (210,211,212,213). The gradual increase of oxidative
damage was generally believed to result in calcium-triggered apoptosis although RBCs lack a
nucleus and mitochondria (214,215). Thus, this process was termed eryptosis (216,217). In
human, erythrocytes have a lifespan of 120 days and the senescent RBCs are removed from
circulations mainly by the Kupffer cells in the liver. In other species, most notably rat and
mouse, phagocytosis may also occur in spleen (209,218, 233).
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1.4.1. Recognition of senescent erythrocytes
Recognition of senescent red cells by macrophages is the key mechanism in the removal
of erythrocytes from the circulation. Phagocytosis of senescent erythrocytes by macrophages
is believed to be a highly regulated process balanced between signaling through
prophagocytic receptors and inhibitory receptors (214,215). Several molecular alterations on
the surface of senescent RBCs had been found to serve as ligands to be recognized by
macrophages. These alterations include modifications in protein carbohydrate moieties (219),
loss of plasma membrane phospholipid asymmetry (210,211,220), and/or clustering of band 3
with subsequent binding of complement or antibodies (221). The recognition could be direct
or through bridging proteins that may interact with RBC ligands (222,223,224,225,226,227).
Following ligation of receptors such as Fcγ receptors, complement receptors, or scavenger
receptors, phagocytosis by macrophages is induced (228,229,230).
1.4.1.1. Autologous immunoglobulin G (IgG)
In physiological circumstances, after the initial phase of reticulocyte maturation,
erythrocytes gradually lose cell volume and hemoglobin, accompanied by an increase in cell
density prior to being removed by macrophage. The removal of these senescent erythrocytes
could be initiated by binding of autologous IgG. In physiological conditions, this is an
efficient process since relatively small numbers (100-500 molecules IgG/cell) of these
autoantibodies are sufficient to trigger phagocytosis and significant IgG binding does not
occur until the last phase of erythrocyte life span (231,232). However, characterization of this
IgG has not led to an unambiguous view (234).
Many in vitro and in vivo data had shown that binding of denatured hemoglobin to
cytoplasmic domains of band 3 causes its oligomerization, which results in the formation of
neoantigens that are recognized by specific IgGs (231,234). Band 3 is the Cl-/bicarbonate
anion exchanger and also the main integral membrane protein. The C-terminal part of the
protein is an integral membrane domain that facilitates the transport of CO2 through the body
by the exchange of Cl− and HCO3− across the erythrocyte membrane (243). The N-terminal
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cytoplasmic domain of band 3 provides the main anchorage site for the cytoskeleton to the
lipid bilayer through ankyrin-mediated binding of the spectrin-actin network. In addition, the
cytoplasmic domain has a high affinity for deoxyhemoglobin (244). The band 3 functions
were found to change with aging, such as a decrease in sulphate transport capacity, changes in
the binding characteristics of ankyrin and the binding of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), a key enzyme of glycolysis. The association of band 3 and
GAPDH inhibits its activity and thereby the rate of ATP production (245,246). Also,
deoxyhemoglobin and especially denatured hemoglobin (hemichromes) has a high affinity for
the cytoplasmic domain of band 3. Thus, band 3 is an important factor in the regulation of
erythrocyte structure and function during aging (232).
Aging-associated breakdown of band 3 is indicated by immunoblot data obtained with
antisera reactive with both the membrane domain and the cytoplasmic domain (214,245). This
is also supported by the functional data showing the aging-related decrease in anion transport
capacity (232). Band 3 clustering may be induced by binding of denatured hemoglobin in
senescent erythrocytes, which causes subsequent IgG binding. However, whether the crucial
changes resulting in senescent red cell antigen activity are caused by band 3 degradation,
cross-linking remain to be described (221,245).
1.4.1.2. CD 47
CD47, also known as integrin-associated membrane protein, is a 47-52 kDa
transmembrane glycoprotein expressed ubiquitously in human tissues including erythrocytes
(236,237). The ligation of CD 47 with its natural ligand thrombospondin-1 induces
programmed cell death in nucleated blood cells (238). The remodeling of cytoskeleton and the
exposure of phosphatidylserine at the outer leaflet of the membrane are the common
characteristics of this death pathway (239). CD47 has been identified as a molecule that may
also be involved in recognition of senescent erythrocytes by macrophages (235). The
expression level of CD47 was speculated to be a mechanism controlling the elimination of
senescent red cells. In vivo, CD47 deficient RBCs are cleared rapidly from the bloodstream
when transfused to normal mice. In vitro, binding of anti-CD47 antibody to normal mouse
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RBCs was found to enhanced phagocytosis (240). Thus macrophages must have specific
receptors capable of recognizing normal RBCs expressing CD47, which initiates signaling
cascades to inhibit macrophage activation and phagocytosis. Experimentally, CD47 on normal
RBC can bind to and activate signal regulatory proteinα (SIRPα) that makes CD47 be a
"marker of self" by signaling through SIRPα against phagocytosis by macrophages. However,
erythrocytes from animals heterozygous for CD 47 survived normally in wild-type mice,
which argue against a gradual disappearance of CD47 as the sole mechanism that regulates
erythrocyte survival. It is more likely that the absence of CD47 triggers other processes that
lead to erythrocyte removal (235).
1.4.1.3. Phosphatidylserine exposure
Exposure of phosphatidylserine at the surface of erythrocytes is another trigger for the
removal of senescent erythrocytes. In erythrocyte pathologies such as sickle cell anemia,
thalassemia and spherocytosis, the decreased erythrocyte survival is associated with an
increase in phosphatidylserine exposure (240,241). It is speculated the decrease in
phospholipid asymmetry might be a normal consequence of physiological aging at the level of
the membrane. Exposure of phosphatidylserine in conjunction with other signals could result
in recognition and removal of senescent erythrocytes by phagocytes (242).
1.4.2. Vesiculation during erythrocyte aging
During aging, erythrocyte volume decreases by 30%, with 20% hemoglobin loss,
resulting in an increased intracellular hemoglobin concentration (244). In parallel, the surface
area and lipid content, mainly cholesterol and phospholipid, decrease as well, implying an
irreversible loss of membrane and cell content by the formation of vesicles (247). These
changes result in the increased osmotic fragility and reduced deformability of erythrocytes,
despite an increase in the surface-to-volume ratio (248). A portion of these vesicles possess
IgG at their surface and exposes phosphatidylserine, similar to the senescent erythrocyte. It
was also found that band 3 is the major membrane protein of vesicles and the hemoglobin
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composition of these vesicles resembles that of the oldest erythrocyte (249,250,251). Vesicles
disappear rapidly, generally within minutes from the circulation in a rat model. The
scavengers are mainly Kupffer cells through recognizing of phosphatidylserine exposed by
the vesicles (247,251).
The vesicles are formed throughout the whole erythrocyte life span but the mechanisms
by which they are generated are poorly understood. It has been proposed, that during the early
life of the erythrocyte, protein modifications such as oxidation, glycation, carbamylation,
nitrosylation or ubiquitinylation already occur (252). In this process, both band 3 and
hemoglobin could be affected. On one hand, the modification of hemoglobin may result in the
binding of denatured hemoglobin to the cytoplasmic domain of band 3 and subsequent
breakdown of the band 3 membrane domains. In turn, this disturbs the organization of the cell
membrane by loss of lipid anchorage and affects the mobility of lipids in successive layers
(253,254), which could lead to vesicle formation whereas the cytoskeleton remains intact. In
vivo, this has been indicated in the erythrocytes of band 3 knockout animals (255,256). On the
other hand, band 3 breakdown could be caused by calcium activated proteases (257,258).
Subsequently, hemoglobin binds to band 3 breakdown products. The band 3 fragments, could
either be driven by aggregation of the associated hemichromes, or be excluded from the
functional complex. Either will cause lateral diffusion and subsequent aggregation of band 3
breakdown products. Eventually, this process increases erythrocyte membrane curvature and
induces vesiculation (259).
Concluded from the above, the vesicle formation caused by the presence of band 3
breakdown products explains the loss of both cell volume and hemoglobin content (232,244).
The vesicles displayed the signal for the removal similar to aged erythrocytes (253,254). In
erythrocytes, non-functional or toxic compound and bad membrane patches are eliminated by
this way. At the end of erythrocyte life, the vesicle formation system appeared to be
overburdened and due to the increasing accumulation of toxin that resulted from dysfunction
cellular defense, the removal of the whole erythrocyte occurs (250).
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1.5. RESEARCH PROJECT
1.5.1. Background
In homeostasis, erythrocytes are constantly renewed to ensure proper tissue oxygenation
(158). In hematopoietic organs, EPO starts to exert its effect on erythroblasts at CFU-E stage
(179,205). The red cell output can increase dramatically under stress erythropoiesis induced
by decreased tissue oxygenation. In general, this is accompanied by an elevation of EPO
plasma levels (168). It is known that the EI is the niche for erythropoiesis in both steady and
stress state. The macrophage/erythroblast and erythroblast/erythroblast interactions are
essential for survival and differentiation of erythroblasts. A diverse array of adhesion
molecules has been characterized to mediate these cellular interactions, among which the
importance of integrins has been established. The α4β1 integrin complex in erythroblasts was
found to contribute to the erythroblast/macrophage interaction by binding to its counter
receptor VCAM-1 on the central macrophage within islands (49). Most recently, macrophage
αv integrin and erythroblast ICAM-4 had been identified to participate in island formation as
well (50,51).
Integrin is a subfamily of heterodimeric transmembrane proteins composed of α and β
subunits. Both subunits are type 1 membrane proteins, have large extracellular ectodomains
and short cytoplasmic tails (260). In mammals, there are at least 18 α subunits and 9 β
subunits, assembling into at least 24 distinct integrins. Integrin α and β subunits are totally
structurally different, with no detectable homology between them. Whereas sequence identity
among α subunits is about 30% and among β subunits it is 45% (261).
Integrins are expressed by a variety of cell types and tissues, e.g. αIIbβ3 on platelets,
α6β4 on keratinocyts, αEβ7 on T cells, dendritic cells and mast cells in mucosal tissues,α4β1
on leukocytes, α4β7 on a subset of memory T cells, the β2 integrin family on leukocytes and
αvβ3 on endothelial cells (262). Ligands for these integrin receptors are mainly extracellular
matrix and cell-surface proteins. Some integrins possess the Arginine-Glycine-Aspartic acids
binding site, which allows integrins to bind to extracellular matrix proteins such as laminins
and fibronectin (263). Upon binding the extracellular ligands, integrins undergo a series of
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conformational changes, generating intracellular signals that trigger many events such as gene
expression, adhesion, differentiation and proliferation, as well as survival or death. Deletion
of integrin subunits in mice causes defects in many processes including development,
vasculogenesis, lymphangiogenesis, thrombus formation, etc. Some integrin antagonists have
been employed as therapeutic drugs to target on interaction of integrins with their ligands.
Abciximab, a humanized anti-β3 antibody that blocks the binding of platelet integrin αIIbβ3
to fibrinogen has been implied to prevent thrombosis clinically (264).
The β3 subfamily of integrins comprises αVβ3 and αIIbβ3 (260). αvβ3 consists of a 125
kDa αv subunit and a 105 kDa β3 subunits. The expression of αvβ3 could be found on many
cell types, including platelets, macrophages, osteoclasts, fibroblasts, some metastatic
melanomas and endothelial cells (265,266,267,268). αvβ3 was found to recognize a wide
range of ligands, such as vitronectin, fibronectin, fibrinogen, osteopontin, that make it play
important roles in several distinct processes, particularly osteoclast mediated bone resorption,
angiogenesis and pathological neovascularisation, and tumor metastasis (269,270,271,272,
273). It was reported that knockout of the gene for β3 enhanced tumorigenesis, angiogenesis,
wound healing, inflammation and atherosclerosis (274,275,276,277).
αIIbβ3 is expressed on platelets and megakaryocytes that make it essential for platelet
aggregation (278). Upon stimulation, platelet surface αIIbβ3 will bind to fibrinogen and von
Willebrand factor to form platelet aggregates. It was proposed that mice deficient of integrin
β3 could be used as the animal model of the human bleeding disorder, Glanzmann
thrombasthenia, resulting from defects in the genes for either the αIIb or the β3 subunit. It was
also reported that occasionally placental defects occur in integrin β3 lacking mice leading to
fetal mortality (278). Postnatally these mice suffer from hemorrhage that results in anemia
and reduced life expectancy. In these animals, extramedullary erythropoiesis is stimulated and
reticulocytes are presented in the peripheral blood (279).
Previously, the characteristics of transgenic mice with very high expression of human
EPO (tg6) have been investigated. Tg6 exhibited increased red blood cells with a hematocrit
levels as high as 0.9 (280). Plasma nitric oxide levels (280) and erythrocyte flexibility were
altered as well (281). Moreover, in tg6 mice, erythrocyte turnover is increased. In line with
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this, erythrocyte population in tg6 mice harbors characteristics of accelerated aging, such as
increased band 4.1a to 4.1b ratio, signs of oxidative stress, or decreased surface CD47 and
sialic acids. In vivo tracking of erythrocytes also revealed dramatically increased engulfment
by their liver macrophages (282).
1.5.2. Objectives
The present study aimed to investigate the pathological characteristics of stress
erythropoiesis in integrin β3 knockout mice in comparison to EPO overexpression mice and
thus to delineate the role of integrin β3 in the formation and stabilization of EI. Specifically, it
was investigated whether the absence of integrin β3 disturbs the adhesion of erythroblasts to
the central macrophage, resulting in premature red cells from EIs into the circulation.
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CHAPTER 2. OWN RESEARCH
PREFACE
This chapter contains a manuscript describing the results of the research project
“Decreased stability of erythroblastic islands in integrin β3 deficient mice” under the
supervision of Prof. Dr. med. Johannes Vogel. This manuscript was submitted for publication.
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Summary 
Erythroblasts proliferate and differentiate in hematopoietic organs within erythropoietic 
islands (EI) composed of erythropoietic progenitor cells attached to a central macrophage. 
This cellular interaction crucially involves the erythroid intercellular adhesion molecule-4 
(ICAM-4) and "v integrin. Because integrins are biologically active as "/! heterodimers 
we asked whether !3 could be a heterodimerization partner of "v integrin in EIs. To this 
end we compared stress erythropoiesis of integrin !3 deficient (!3-/-) mice that exhibit 
impaired hemostasis due to platelet dysfunction with that of systemically erythropoietin-
overexpressing (tg6) mice. Despite having much less erythropoietic stimulation compared 
to tg6 mice, peripheral blood of !3-/- mice contained more erythrocytes of a lower 
maturity stage. Unexpectedly, membranes of peripheral erythrocytes from !3-/- mice 
contained calnexin, a chaperone that is normally completely lost during terminal 
differentiation of reticulocytes prior to their release into the circulation. In contrast to 
erythropoietin-overexpressing mice, the erythropoietic subpopulations representing 
orthochromatic erythroblasts and premature reticulocytes as well as the number of cells 
per EI were reduced in !3-/- bone marrow. In conclusion, absence of integrin !3 impairs 
adhesion of the latest erythroid developmental stage to the central macrophage of EIs 
resulting in preterm release of abnormally immature erythrocytes into the circulation.  
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Introduction 
Proliferating and differentiating erythroblasts require a specialized microenvironment 
termed erythroblastic island (EI) (Allen and Dexter 1982, Hanspal and Hanspal 1994, 
Mohandas and Prenant 1978), normally (for review see e.g. (An and Mohandas 2011, 
Manwani and Bieker 2008, Mohandas and Chasis 2010)) composed of a F4/80 
expressing central macrophage surrounded by about 5-30 cells from nucleated 
proerythroblasts through multilobulated reticulocytes (Lee, et al 1988). During 
differentiation orthochromatic erythroblasts extrude their nucleus that is subsequently 
engulfed by the central macrophage, a mechanism crucially requiring macrophage – 
erythroblast interactions (Mohandas and Chasis 2010). Moreover, this interaction 
enhances proliferation of erythroblasts by speeding up the G0/G1 phase to complete more 
cell divisions per time unit and, thus, generating more reticulocytes (Hanspal and Hanspal 
1994). In addition, erythroblast – erythroblast interactions regulate survival of 
erythroblasts through Fas – FasL interaction (Liu, et al 2006). In man the direct contact 
between erythroblasts is also essential for homotypic signaling between erythroblasts 
within the EI niche as a mechanism for regulating GATA-1 activity to complete terminal 
differentiation (De Maria, et al 1999).  
The above-mentioned interactions are mediated by a diverse array of adhesion 
molecules. Erythroblast macrophage protein (Emp) was the first molecule described to be 
involved in the attachment of erythroblasts to the central macrophage and to neighboring 
erythroblasts (Hanspal and Hanspal 1994). Subsequently "4!1 integrin in erythroblasts 
and vascular cell adhesion molecule 1 (VCAM-1) in central macrophages (Sadahira, et al 
1995) and erythroid intercellular adhesion molecule-4 (ICAM-4, also known as the 
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Landsteiner and Weiner (LW) blood group glycoprotein (Bailly, et al 1994)) as well as 
macrophage "v integrin was found to contribute to the erythroblast – macrophage 
interactions (Lee, et al 2006). 
Since it has been shown that "IIb!3 and "v!3 integrins can interact with ICAM-4 
on red blood cells (RBCs) (Hermand, et al 2004, Hermand, et al 2003), the present study 
aimed to compare characteristics of stress erythropoiesis in integrin !3 deficient mice 
with that of Epo overexpressing mice (tg6). Integrin !3 deficient mice resemble human 
Glanzmann thrombasthenia characterized by mild gastrointestinal and cutaneous 
hemorrhage due to impaired platelet aggregation (Hodivala-Dilke, et al 1999). Tg6 mice 
have independent of oxygen tension about 10-times elevated Epo plasma levels resulting 
in hematocrit values of 0.8-0.9 (Ruschitzka, et al 2000). Despite having less stimulated 
erythropoiesis than tg6 mice, peripheral blood of !3 deficient mice contained RBCs of a 
lower maturation stage. Surprisingly, erythrocytes from !3-/-, but not from tg6 mice, 
contained calnexin, an endoplasmatic reticulum glycoprotein chaperone that is normally 
completely lost during terminal RBC differentiation (Patterson, et al 2009). Moreover, 
the erythropoietic subpopulation representing orthochromatic erythroblasts and premature 
reticulocytes as well as the number of cells per EI was reduced in !3-/- bone marrow. 
These findings suggest that !3 integrin could be involved in attachment of late 
developmental stages of RBCs to the EI.  
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Materials and Methods 
Animals. Mice aged between 4 and 6 months were used and genotyped as described 
(Hodivala-Dilke, et al 1999, Ruschitzka, et al 2000). All experiments conformed 
governmental and institutional guidelines. 
 
Analysis of peripheral blood. Hematological parameters were determined with standard 
techniques. Plasma erythropoietin concentrations were measured with EPO-TracTm 125I 
RIA kit (DiaSorin) and RBC osmotic fragility, flexibility and life-span as described 
(Bogdanova, et al 2007, Vogel, et al 2003). RBC membrane proteins analysis 
(Bogdanova, et al 2007) revealed for ß3-/- mice an additional band that was analyzed by 
mass spectrometry (Functional Genomics Center Zürich). Optical density ratios between 
bands 4.1a and 4.1b and the extra band and band 4.2 were determined as described 
(Gassmann, et al 2009). RBCs were also analyzed flowcytometrically (cf. below) for 
Annexin V-FITC binding (apoptosis detection kit, PromoKine), reticulocyte number 
(Retic-COUNT, BD Biosciences), remnants of endoplasmatic reticulum (ER-tracker®, 
Invitrogen) in reticulocytes (Retic-COUNT positive red cells) and CD71 and CD44 
expression.  
 
Fluorescence-Activated cell Sorting (FACS) and flow cytometry of hematopoietic 
tissues. Bone marrow and spleen single-cell suspensions were immunostained for 
Ter119, CD71, and CD44 and CD47 (all from BD Biosciences) after blocking cellular Fc 
receptors with 5% rat serum and analyzed using a flow cytometer (FACSCalibur or 
Gallios, Becton Dickinson) and the Winmdi or Kaluza software. Hematopoietic cells 
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labeled with CD44 and TER119 antibodies were also sorted (Aria III, 5L, Becton 
Dickinson), transferred onto slides and staining with May-Grunwald solution.    
 
Histological analysis of hematopoietic tissues. Perfusion fixed (4% parformaldehyde, 
PBS) and decalcified bone and spleen sections were stained with Prussian blue, 
Hematoxylin and eosin or, after auto-fluorescence quenching (Schnell, et al 1999), with 
FITC-labeled anti mouse F4/80 (Abcam) and PE-labeled anti mouse Ter119 antibodies 
and 4#,6-Diamidino-2-phenylindole dihydrochloride (DAPI, Sigma) to identify EIs in 
bone marrow. EI density and Ter119 positive cells per EI were determined (cf. legend to 
fig. 5A) in 10 randomly selected, non-overlapping fields of bone marrow sections per 
mouse.  
 Other bone marrow sections were immunostained for fibronectin (rabbit anti-
human fibronectin, ICN/Cappel; goat anti-rabbit IgG, DyLight 649 labeled, Jackson 
ImmunoResearch Lab.), coverslipped using a moviol-based (Calbiochem) embedding 
medium (Osborn and Weber 1982) containing 1,4-Diazobicyclo-[2.2.2]-Octan (Sigma) 
and hardened over night. After image acquisition (HPX 120 C, Axioimager.Z2, Axiocam 
HRm CCD camera, Axiovision software version 4.5, Zeiss) average optical density levels 
(oDL) of single bone marrow vessels were determined (MCID Analysis 7.0) by taking 
into account only pixels exceeding an oDL of 45 (20% above average background value) 
and excluding elements with a size below 10 pixels (cf. supplemental fig. 7B). 
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Analysis of bone structure. Cortical and trabecular microarchitecture of femurs was 
assessed by micro-computed tomography (MicroCT40 (Scanco Medical) scanner as 
described (Hildebrand, et al 1999, Hildebrand and Ruegsegger 1997, Kohler, et al 2007). 
 
Statistics. Results are expressed as means +SEM. Statistical significances were assessed 
using a 2-tailed Student t-test for unpaired samples with Bonferroni correction and 
labeled as * = p<0.05, ** = p< 0.01 or *** = p<0.001 when compared to the respective 
wt controls or as # = p<0.05, ## = p< 0.01 or ### = p<0.001 for comparison between !3-/- 
and tg6 mice.  
 
 
Results 
Erythropoiesis is mildly stimulated in integrin !3-/- mice. In line with our previous 
reports (Bogdanova, et al 2007, Ruschitzka, et al 2000, Vogel, et al 2003), average 
hematocrit of the tg6 mice used here was 0.83 whereas it was 12% lower in !3-/- but not 
!3+/- mice compared to wt littermates. (fig. 1A). Accordingly in four mice of each 
genotype, hemoglobin concentration (g/dl: wt: 16.05 ±0.15; !3-/-: 12 ±0.7, p < 0.05) and 
red cell count (*106/$l: wt: 10.82 ±0.37; !3-/-: 7.7 ±0.89, p < 0.01) was reduced in !3-/- 
mice. Erythrocyte parameters such as MCH (pg: 15 ±0.01; !3-/-: 16 ±0.02, ns) and 
MCHC (g/dl: wt: 34 ±0.03; !3-/-: 32 ±1, ns) were unchanged suggesting normal 
hemoglobin synthesis. RBC volume was increased in !3-/- mice (MCV (fL): wt: 44 ±1; 
!3-/-: 49 ±2, p < 0.05) with a slightly higher scatter in !3-/- mice (RDW: wt: 20.9 ±0.7; !3-
/-: 21.3 ±1.1, ns). 
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 The 1.5-fold and 5.5-fold splenic enlargement in !3-/- and tg6 mice, respectively, 
indicates stimulated extramedullary erythropoiesis that is, however, much stronger in the 
Epo-overexpressing mice (fig. 1B). Accordingly, plasma Epo levels were unaltered in !3-
/- (!3-/-: 20.49 ±1.45 U/L; wt: 20.35 ±0.85 U/L respectively, n = 10). Flow cytometric 
erythrocyte size determination and peripheral blood smears did not reveal morphological 
alterations in !3-/- mice (supplemental figs. 1A and 3). Prussian blue staining of bone 
marrow and spleen sections did not indicate altered iron storage in !3-/- mice 
(supplemental fig. 1B). 
 
Red cell survival is normal in integrin !3-/- mice. In wt mice RBC half-life was within 
literature values (Manodori and Kuypers 2002), namely 21.6 ±0.67 days (n = 8). In 
integrin !3-/- mice half-life was slightly (17.9 ±2.96 days (n = 5)) but not significantly (p 
= 0.29) lower, maybe because of the higher data scatter in !3-/- mice compared to their wt 
littermates (coefficient of variation 36.93% vs. 8.99%). This just marginally reduced red 
cell survival together with limited splenomegaly and unaltered plasma Epo levels suggest 
mild erythropoietic stimulation in !3-/- mice.  
 
Mechanical properties of erythrocytes from integrin !3-/- mice are normal. 
Mechanical properties of erythrocytes are age-dependent with young cells being more 
flexible and resistant to osmotic stress. Erythrocytes of tg6 mice were reported to be more 
flexible and having a higher osmotic resistance (Bogdanova, et al 2007, Vogel, et al 
2003). Compared to wt littermates, !3-/- mice showed a trend towards increased 
erythrocyte flexibility at higher shear forces (supplemental fig. 2A) but unchanged 
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osmotic resistance (50% lysis of RBCs: wt: 0.5581%, !3-/-: 0.5545%, supplemental fig. 
2B).   
 
Peripheral erythrocytes of integrin !3-/- mice show a higher degree of immaturity 
than those of tg6 mice. Compared to wt, reticulocyte counts were significantly and, 
more surprisingly, similarly increased in !3-/- and tg6 mice. Maturity of the peripheral red 
cells was therefore assessed by additional measurements (figs. 2 & 3). 
The skewness of the intensity distribution directly impacts the geometric mean (cf. 
fig. 2B) that can be used to estimate reticulocyte age distribution (Wiczling and 
Krzyzanski 2007, Wiczling and Krzyzanski 2008). Average fluorescence intensity of 
Retic-COUNT® stained reticulocytes from !3-/- was significantly higher than of those of 
their wt littermates whereas tg6 reticulocytes had the same staining intensity as control 
mice. Accordingly, Brilliant-Kresyl blue stained blood smears revealed more chromatin 
in !3-/- than in wt or tg6 reticulocytes (supplemental fig. 3). Using flow cytometry, 
expression of the transferrin receptor CD71 was assessed because this protein diminishes 
with erythroblast maturation (Kina, et al 2000). Compared to wt controls a similar and 
significant increase in cells positive for CD71, was observed in !3-/- and tg6 mice. Next, 
we examined on RBCs expression of the adhesion molecule CD44 that might be more 
specific for late erythropoietic developmental stages (Chen, et al 2009). Compared to wt 
littermates as well as to tg6 mice !3-/- mice had significantly more CD44 positive RBCs. 
In contrast, RBCs of tg6 mice showed the same CD44 expression as their wt controls. 
Another sign of immaturity are remnants of the endoplasmatic reticulum (ER) that were 
considerably (+50%) more increased in !3-/- than in tg6 RBCs. Red cell aging, next to 
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other stresses, results in phosphatidylserine exposure. As reported previously (Foller, et 
al 2007) tg6 erythrocytes bound significantly more Annexin V whereas !3-/- RBCs 
showed unaltered Annexin V binding (fig. 2A). Tg6 erythrocytes express less CD47 
(Bogdanova, et al 2007), a marker that declines with RBC aging (Oldenborg, et al 2000). 
In contrast to tg6 RBCs, !3-/- red cells displayed increased CD47 expression by about 
42% compared to their wt littermates (fig. 2B). 
 Next, we determined the band 4.1a / 4.1b ratio of RBC ghost proteins that 
increases with RBC aging (Inaba and Maede 1988). Figure 3A shows examples of silver 
stained SDS-polyacrylamide gel electrophoresis (SDS-PAGE). For both wt strains used 
the band 4.1a / 4.1b ratio was within the values reported previously for mice (Bogdanova, 
et al 2007, Inaba and Maede 1988). In line with our previous work the band 4.1a /4.1b 
ratio was increased in tg6 mice compared to their wt controls (fig. 3B), which had been 
interpreted as accelerated aging of the transgenic RBCs (Bogdanova, et al 2007). In 
contrast, in !3-/- mice the band 4.1a /4.1b ratio was dramatically reduced by about 75% 
suggesting a reduced average age of peripheral !3-/- RBCs.  
 Interestingly, silver-stained SDS-PAGE of RBC membrane extracts from !3-/- 
mice showed an extra band at around 90kD (fig. 3A), which was identified as calnexin 
with minor contamination with other proteins most likely from platelets (cf. supplemental 
fig. 4). Calnexin, an endoplasmatic reticulum glycoprotein chaperone, is normally 
completely lost before reticulocytes are released into the circulation (Patterson, et al 2009) 
was absent in tg6 RBC membrane preparations (fig. 3A & 3C) implying even abnormal 
immaturity of the peripheral RBCs from !3-/- mice. These data suggest a reduced stability 
of the erythropoietic niche in !3 deficient mice. 
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The latest erythroid developmental stage is reduced in bone marrow of !3-/- mice. 
Using the flow cytometric assay developed by Liu et al. (Liu, et al 2006), we next 
examined the erythroblast differentiation stages in hematopoietic tissues. Based on 
Ter119 and CD71 expression, bone marrow and spleen cells were classified as 
proerythroblast (ProE) and cells expressing high levels of Ter119 (cf. supplemental fig. 
5).  
Splenic erythroblasts (Ter119 positive cells) were significantly increased in both 
genetically modified mouse lines (n = 8, all in %: !3+/+: 10.7 ±2.56; !3-/-: 28.6 ±4.85, 
p<0.01 vs. !3+/+; BL6: 7.2 ±2.65; tg6: 66.7 ±2.74, p<0.001 vs. BL6) but not in bone 
marrow (n = 8, all in %: !3+/+: 34.8 ±2.31; !3-/-: 42 ±3.86; BL6: 49.2 ±2.16; tg6: 50.5 
±2.11). The proportion of the different erythroblast subsets Ery.A, Ery.B and Ery.C in 
bone marrow was clearly different between !3-/- and tg6 mice. Whereas compared to their 
respective wt controls the percentage of ProE and Ery.A was similar in !3-/- and tg6 mice, 
the percentage of Ery.B was increased in !3-/- but lower in tg6 mice. Conversely, the 
percentage of the most mature erythroblast subset Ery.C that represents orthochromatic 
erythroblasts as well as premature reticulocytes (Liu, et al 2006) was reduced in !3-/- but 
increased in tg6 mice (fig. 4A). This finding is in line with more immature peripheral red 
blood cells we found in !3-/- mice. Interestingly, the high increase of Ery.C in tg6 mice 
compared to their wt controls might suggest delayed RBCs release from the bone marrow, 
which fits to our previous report that tg6 RBCs share features of young and aged 
erythrocytes (Bogdanova, et al 2007). In the spleen of tg6 mice the increase of ProE was 
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much more pronounced compared to !3-/- mice (11-fold vs. 4.8-fold) but no other 
differences between both mouse lines were found in this organ (fig. 4B). 
 A study using cultured splenic proerythroblasts and bone marrow cells obtained 
from mice infected with the anemia-inducing strain of Friend leukemia virus (FVA) 
suggests that later erythropoietic developmental stages may resolve better when stained 
with antibodies against CD44 (Chen, et al 2009). Therefore, we also analyzed the 
expression of CD44 on bone marrow and spleen cells of our mice. Compared to Chen et 
al. (Chen, et al 2009) our flow-cytometrically obtained pattern looked differently. 
Consequently, we sorted the cells and identified their morphology after May-Grunwald 
staining (cf. supplemental fig. 6). In CD44 and TER119 stained mouse bone marrow cells 
four erythropoietic subopulations could be distinguished. Subpopulation I corresponded 
to ProE and Ery.A, II to EryA, III to some EryB and mainly Ery.C as defined by Liu et al. 
(Liu, et al 2006) and IV mainly to reticulocytes but also some erythrocytes similar to the 
definition from Chen et al. (Chen, et al 2009). In spleen cells however subpopulations I 
and II could not be separated reliably. Whereas the proportion of splenic erythropoietic 
stages in spleens of !3-/- and tg6 mice was similarly altered compared to their respective 
wt control (fig. 4D), clear differences were found in the bone marrow. As for CD71 the 
most striking differences between both genetically modified mouse lines were found in 
the last erythroid stage (IV, fig. 4C). Compared to their non-transgenic littermates the 
fraction of population IV was reduced to about 40% in !3-/- mice whereas in tg6 mice in 
was increased by about 30%. Moreover subpopulation III was increased in !3-/- mice but 
reduced in tg6 mice although this did not reach the level of statistical significance (fig. 
4C). Note that erythropoietic stimulation resulted in an inversion of the ratio between 
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subpopulation III (or Ery.B) and IV (or Ery.C) only in !3-/- but not in tg6 (cf. fig. 4A & C 
and also supplemental fig. 6). 
 
!3-/- EIs contain less erythroblasts. Our above-mentioned flow-cytometric data 
prompted us to next visualize bone marrow EIs with ani-F4/80 and anti-Ter119 
antibodies (fig 5A). Compared to respective wt controls, EI density in femur marrow was 
unchanged in !3-/- mice but significantly increased in tg6 mice. However, significantly 
less (-30%) erythroblasts per island were observed in !3-/- whereas in tg6 mice it was 
comparable to wt controls (fig. 5B).  
 
Fibronectin immunoreactivity of bone marrow is increased in !3-/- and decreased in 
tg6 mice. Quantitative immunofluorescence of fibronectin staining in the bone marrow 
revealed quite stable measurements. Compared to their respective wt controls vessel-
associated fibronectin staining intensity was significantly increased in !3-/- mice but 
decreased in tg6 mice (fig. 6, supplemental fig. 7). 
 
Three dimensional bone structure of !3-/- mice is not altered. Epo induces indirectly 
trabecular bone loss (Singbrant, et al 2011) to free marrow space for erythroid cell 
expansion. Mice lacking !3 were reported non-quantitatively to have more but 
dysfunctional osteoclasts resulting in increased cortical and trabecular bone mass 
(McHugh, et al 2000). In contrast, we quantified the three-dimensional structure of the 
femurs using micro-computed tomography imaging (Hildebrand, et al 1999). Using this 
technique we did not observe significant changes in the cortical bone in none of our mice. 
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However, trabecula of tg6 bones showed reduced numbers, increased spacing but 
unaltered thickness (supplemental fig. 8B). In contrast, !3-/- mice displayed a slight non-
significant trend towards reduced trabecular spacing and increased trabecular number in 
line with McHugh et al. (McHugh, et al 2000). Hematoxylin and eosin stained bone 
sections showed no obvious differences regarding the trabecular or cortical bone structure 
in !3-/- mice (supplemental fig. 8C).  
 
 
Discussion 
Despite having only mildly stimulated erythropoiesis (unaltered plasma Epo values, 
unchanged EI density in bone marrow, minor splenic enlargement, normal RBC life-span) 
integrin !3 deficient mice exhibit peripheral RBCs of a lower maturity grade (more 
intense RNA staining in reticulocytes, increased CD44 and CD47 expression, increased 
band 4.1a / 4.1b ratio) in comparison to tg6 mice with maximally stimulated 
erythropoiesis. Of note, !3-/- mice retain calnexin in their peripheral erythrocytes 
indicating even abnormal immaturity. Moreover, in bone marrow from !3 deficient but 
not erythropoietin overexpressing mice the late stage erythroblasts are reduced. Together 
with the finding of reduced numbers of erythroblasts per EI in !3 deficient mice these 
observations suggest that integrin !3 might play a role in the stabilization of the 
erythopoietic islands, most likely during the late maturation stage just before reticulocyte 
release. 
Central macrophages of EIs express "v integrin and erythroid ICAM-4 (LW 
glycoprotein) that is critical for EI formation (Lee, et al 2006). However, integrins, 
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ligands for ICAMs, are functional only as heterodimers composed of one " and one ! 
subunit. Whereas ! subunits combine with different " subunits, " subunits bind only one 
! subunit with the exception of "v, "4 and "6 (Hynes 1992). Thus, the question 
remained as to the binding partner of "v integrin on the central macrophage of EIs. A 
hint to answer this question was the observation that the red cell ICAM-4 can bind 
"IIb!3 as well as "v!3 integrin heterodimers, both present on platelets (Hermand, et al 
2004, Hermand, et al 2003). Genetic deficiency of "IIb and !3 integrins results in a 
bleeding disorder known as Glanzmann thromboplasthenia (Coller, et al 1987) as in the 
!3 integrin deficient mice used here (Hodivala-Dilke, et al 1999). In contrast, ICAM-4 
deficient animals do not show alterations in hemostasis, hematocrit or hemoglobin levels 
(Lee, et al 2006), probably because during hemostasis platelet integrins bind to 
extracelluar matrix molecules such as fibrinogen, fibronectin, von Willebrand factor, 
thrombospondin and vitronectin (Felding-Habermann and Cheresh 1993, Hynes 1992) 
and not ICAM-4. However, binding of RBCs to the forming thrombus requires 
interaction of ICAM-4 with "IIb!3 and/or "v!3 integrins (Hermand, et al 2004, 
Hermand, et al 2003) although this has not yet been proven in vivo (Lee, et al 2006). Our 
present data suggest an additional function of integrin !3, namely, stabilizing EIs as 
heterodimerization partner of "v integrin on central macrophages. This is concluded from 
the observation that in contrast to tg6 mice with much higher erythropoietic stimulation 
!3 integrin deficient mice exhibit abnormally immature peripheral RBCs (figs. 2, 3 and 
supplemental figs. 3 & 4), EI’s with significantly less Ter119 positive cells (fig. 5B) and 
a reduced erythroid bone marrow population representing orthochromatic erythroblasts 
and premature reticulocytes (figs. 4C, 4E). 
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It could be shown that different hematopoietic cell lines bind to ICAM-4, which 
involves "4!1 integrin and "v-family integrins but !3 and "v integrin specific antibodies 
failed to reduce binding of these hematopoietic cell lines to ICAM-4 (Spring, et al 2001). 
Maybe the stable cell lines used in the latter study do not entirely reflect the dynamic in 
vivo situation, an interpretation in line with the fact that the same study also shows that 
only 6 out of 12 tested hematopoietic cell lines bound ICAM-4 (Spring, et al 2001). 
Moreover, the same group showed later that the "v integrin is indeed involved in binding 
of erythroblasts to the central macrophage (Lee, et al 2006). However, the whole picture 
might be more complex as "4!1 integrin can in addition to ICAM-4 (Spring, et al 2001) 
also interact with the vascular cell adhesion molecule-1 (VCAM-1) within EIs (Sadahira, 
et al 1995). In this case, "4!1 integrin is expressed on erythroblasts and VCAM-1 on the 
central macrophage (Sadahira, et al 1995). Another hint for the importance of the integrin 
– ICAM-4 – interaction for RBC production suggests expression and secretion of a 
soluble ICAM-4 isoform by erythroblasts (Lee, et al 2003) that could compete with the 
membrane bound ICAM-4 for integrin counterreceptors and thus play a role for the final 
detachment of reticulocytes from the central macrophage. If one heterodimerization 
partner of "v integrin is missing, e.g. !3 as we suggest, ICAM-4 dependent EI stability 
could be weakened and, thus, lower concentrations of soluble ICAM-4 could result in a 
preterm release of late stage erythroblasts or premature reticulocytes from the EI. 
Moreover, our data suggest that strong erythropoietic stimuli per se such as massive 
systemic Epo overexpression in tg6 mice do not trigger preterm release of reticulocytes 
(figs. 3, 4C, 5 and supplemental fig. 3). 
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 Adhesion of the whole EI to the extracellular matrix might be important as well. 
Maturating EIs migrate towards the bone marrow sinusoids where young RBCs are 
released into the circulation (Yokoyama, et al 2003). Whereas in early developmental 
stages Epo plays the predominant role, interactions of differentiating RBCs with the 
extracellular matrix e.g. fibronectin are crucially important for the second phase of 
maturation (Eshghi, et al 2007) and might even provide proliferative stimuli for 
hematopoietic cells (Vuillet-Gaugler, et al 1990, Weinstein, et al 1989). The fibronectin 
dependent late phase of RBC maturation correlates with the migration of the EIs towards 
the sinusoids and both mechanisms might be regulated by interplay between integrin !1 
and !3 (Danen, et al 2002). Using quantitative immunofluorescence we found in !3-/- 
mice compared to their wt controls bone marrow fibronectin to be increased whereas in 
tg6 mice it was decreased (fig. 6). In !3-/- mice increased fibronectin expression could be 
a compensatory mechanism to enhance binding of the premature RBCs, erythroblasts or 
the whole EI to the extracellular matrix to prevent the release of cells of even lower 
maturity into the circulation. Moreover, this compensatory mechanism could in !3-/- mice 
enhance also the second phase of erythroid maturation that requires fribronectin 
interaction with "4!1 integrin (Eshghi, et al 2007), which should not be altered in !3-/- 
mice. This interpretation fits to the significant higher fraction of Ery.B in the bone 
marrow of !3-/- mice (fig. 4A). In parallel, more fibronectin could facilitate migration of 
EIs towards the sinusoids resulting in reduced Ery.C (or group IV) population as 
observed in !3-/- bone marrow (fig. 4A & C). Conversely, bone marrow fibronectin 
staining intensity was decreased in tg6 mice. Tg6 mice need to fight against the 
uncontrolled RBC production. Because they cannot escape the early stage of erythroid 
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differentiation and expansion due to transgenic Epo production reduced fibronectin 
expression in tg6 mice could represent a compensatory mechanism for decelerating / 
inhibiting the fibronectin-dependent but Epo-independent second phase of erythroid 
differentiation (Eshghi, et al 2007) and migration of the EIs towards the sinusoids. This 
would keep the young erythrocytes longer than normal in the bone marrow. Indeed, we 
previously demonstrated that RBCs from tg6 mice share features of young as well as 
senescent red cell (Bogdanova, et al 2007), which fits to this interpretation.  
 Bone remodeling to reduce trabecular volume density is crucial for erythropoiesis 
and inhibition of osteoclasts blunts the erythropoietic response to Epo (Singbrant, et al 
2011). Accordingly, in tg6 mice bone marrow volume was increased on cost of trabecular 
number with increased trabecular spacing (supplemental fig. 8), an observation in line 
with our previous findings (Heinicke, et al 2006). In contrast, integrin !3 deficient mice 
were reported to have impaired bone remodeling as shown by an enhanced density of 
tailbones that, however, contain mainly yellow marrow (Lee and Rosse 1979) and 
histological examples of distal femora suggesting an increased bone mass (McHugh, et al 
2000). In addition, this latter study shows in !3-/- mice more osteoclasts that appear 
dysfunctional although they retain resorptive capacity when cultured on whale dentin. 
Unfortunately, no quantifications of these observations are provided. Quantitative micro-
computed tomography based analysis of femora, however, did not reveal significant signs 
for osteosclerosis in !3-/- mice (supplemental fig. 8B). On the other hand, altered bone 
remodeling should affect the EI density (Singbrant, et al 2011) (that was unchanged in 
!3-/- mice) rather than the number of erythroid progenitors per island (that was reduced in 
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!3-/- mice). Thus, it is unlikely that the probably marginally disturbed bone remodeling in 
!3-/- mice could be causal for the observed instability of their EIs.   
 In conclusion, by comparing stress erythropoiesis of Epo overexpressing mice and 
integrin !3-/- mice we discovered a new functional role of integrin !3 for stabilization of 
erythropoietic islands. Our findings suggest that integrin !3 is important during the very 
late stage of red cell production by delaying release of premature reticulocytes. 
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Figure legends 
Fig 1.  Comparison of the strength of erythropoietic stimulation in integrin !3 deficient 
and Epo overexpressing (tg6) mice. (A) In homozygous !3 deficient mice the hematocrit 
is slightly but significantly decreased. Systemic overexpression of Epo results in extreme 
hematocrit values as high as 82% in line with our previous reports (Bogdanova, et al 
2007, Ruschitzka, et al 2000, Vogel, et al 2003) (n % 5). (B) Stimulation of erythropoiesis 
results in splenic enlargement in both genetically modified mouse lines that is, however, 
stronger in tg6 mice (n % 5).  
 
Fig 2. Analysis of peripheral RBCs in integrin !3-/- and tg6 mice. (A) This bar graph 
shows for both genetically modified mouse lines the fold changes of the parameters in 
relation to their respective wt controls (set to 1). Reticulocyte counts were significantly 
and similarly increased in both !3-/- and tg6 mice but only !3 deficient mice showed a 
significantly higher reticulocyte staining intensity (n % 6, cf. also supplemental fig. 3). 
The percentage of CD71 positive RBCs was similarly increased in !3-/- and tg6 mice (n % 
6) whereas the CD44 positive fraction was significantly increased only in !3-/- mice (n = 
5). Accordingly, the ER-tracer dye positive reticulocyte faction was higher in !3-/- mice 
(n = 5). Binding of annexin V to RBCs, marking the eryptotic RBC fraction, did not 
differ significantly between !3 deficient mice and their wt controls. In contrast, according 
to our previous findings (Foller, et al 2007) annexin V binding was significantly 
increased on tg6 erythrocytes (n = 6). (B) In addition, RBCs from !3-/- displayed 
increased immunoreactivity for CD47 on their surface as evident from right-shift of the 
population (image) that is quantified by the geometric mean  (bar graph, n = 4).  
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Fig 3. Silver-stained SDS–polyacrylamide gel electrophoresis of erythrocyte membrane 
proteins. (A) In !3 deficient mice an additional band was detected that was identified as 
calnexin using mass spectroscopy (cf. supplemental fig. 4). (B) Quantification of the 
band 4.1a/4.1b ratio revealed in !3 deficient mice a reduction whereas in accordance with 
our previous study (Bogdanova, et al 2007) this ratio was increased in tg6 (n % 5). (C) 
Quantification of the calnexin band intensity in relation to the band 4.2 intensity revealed 
practically no signal in tg6 mice whereas it was clearly detectable in !3-/- mice (n % 5). 
 
Fig 4. Analysis of erythroblast subsets in bone marrow and spleen. (A) In the bone 
marrow ProE were significantly increased to a similar extend in both !3-/- and tg6 mice. 
Ery.A were not altered whereas Ery.B were significantly increased in !3-/- mice but 
decreased in tg6 mice. The Ery.C population, representing orthochromatic erythroblasts 
and premature reticulocytes, was significantly decreased in !3-/- but increased in tg6 mice 
(n = 5). (B) In the spleen no differences between !3-/- and tg6 mice were found regarding 
the fraction of the different erythroblast subpopulations (n = 5).  
Panel (C) and (D) show the different erythroblast subpopulations (definition see text and 
supplemental fig. 5) after staining with FITC-conjugated anti-CD44 and PE-conjugated 
anti-Ter119 antibodies. (C) In line with the findings obtained with CD71 the most 
obvious difference between !3-/- and tg6 mice was the marked decrease in the latest 
erythropoietic developmental stage (subpopulation IV) in !3-/- but an increase in tg6 bone 
marrow compared to wt controls. Also the pattern of the other subpopulations was 
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comparable to that observed with CD71. (D) As for CD71, in the spleen there was no 
difference between !3-/- and tg6 mice regarding the erythropoietic subpopulations.   
 
Fig 5. Analysis of EIs in bone marrow. (A) Representative image of a bone marrow EI 
with the macrophage labeled with an antibody directed against F4/80 (green) and the 
erythroblasts labeled with an antibody against TER119 (red). Original magnification 
1000x. Only those TER119 positive cells were considered to be associated with a central 
macrophage that were 25% or less of the cell diameter distant from a F4/80 positive cell 
(4 gray squares = cell diameter, yellow square: 25% of the diameter of that cell). (B) 
Quantification of the EI density per 10 fields of view per animal and the number of 
erythroblasts attached to a macrophage. Compared to wt controls there was no difference 
in !3-/- mice regarding EI density whereas in tg6 mice it was significantly increased (left 
panel). In !3-/- mice there was a significant reduction of cells per EI whereas tg6 mice did 
not show a difference compared to their wt controls regarding this parameter (right panel, 
n = 10). 
 
Fig 6. Assessment of local fibronectin expression in bone marrow. Examples of images 
and quantification procedure cf. methods and supplemental fig. 7. Vessel-associated 
fibronectin staining intensity (8-bit optical density level: 0 = black, 255 = white) was 
increased in !3-/- mice but reduced in tg6 mice compared to their wt controls (n = 4). No 
difference was detected between both wt strains used. 
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Supplemental figures 
 
S-fig 1.  (A) Size (left panel, n = 18) and gross morphology of erythrocytes (original 
magnification 400x, right panel) were not altered in !3-/- mice (cf. also supplementary 
fig. 3). (B) Prussian blue staining (original magnification 400x) revealed compared to wt 
controls no difference in iron deposition neither in bone marrow nor in spleens of !3-/- 
mice. 
 
S-fig 2. (A) Mechanical properties of !3-/- erythrocytes were not significantly altered as 
assessed by recording elongation of the erythrocytes at shear stresses between 0.13 and 
25.25 s-1 (10.1 mPa*s, solution #1) or 0.29 and 58.5 s-1 (23.4 mPa*s, solution #2). Higher 
shear stresses revealed a trend towards increased flexibility in !3-/-mice (n = 6). (B) 
Osmotic fragility of !3-/- RBCs was indistinguishable from that of their wt controls (n " 
6). 
 
S-fig 3. Blood smears were stained with Brillian-Kresyl blue to visualize reticulocytes. 
Shown are selected fields containing an amassment of reticulocytes (labeled with green 
arrowheads). Reticulocytes from !3-/- mice showed more and denser staining. Original 
magnification 1000x.  
 S-fig 4. (A) MASCOT’s probability based Mowse scores of the proteins identified in the 
additional 90kD band found in the gels from !3-/- peripheral RBC membrane preparations 
(cf. fig. 3A). Scores >52 indicate identity or extensive homology (p < 0.05; green hatched 
area indicates non-significant results). Calnexin has a score of 291 indicating that the 
probability that this protein is not present in the extra band is smaller than 10-29 %. 16 
peptide query matches and 9.5% sequence coverage were obtained and mass accuracy for 
all peptides was better than 20.5 ppm. Marked are also all other significant protein hits 
from mice found in the extra band. (B) The whole amino acid sequence of calnexin is 
shown with the identified peptide fragments marked (bold and underlined). 
 
S-fig 5. Bone marrow and spleen cells (shown here: bone marrow) were classified based 
on Ter119 and CD71 expression as proerythroblast (ProE) and cells expressing high 
levels of Ter119. The population pattern was similar for bone marrow and spleen. The 
whole population of Ter119high cells, representing later stages of erythroblast 
development, was further subdivided according to its CD71 expression level and forward 
scatter (FSC). The resulting three subpopulations were identified as Ery.A (Ter119high 
CD71high FSChigh), Ery.B (Ter119high CD71high FSClow) and Ery.C (Ter119high CD71low 
FSClow), corresponding to basophilic, polychromatic and orthochromatic erythroblasts 
and reticulocytes, respectively. 
 
S-fig 6. Flow cytometric analysis of bone marrow (A) and spleen cells (B) after staining 
with fluorescence labeled antibodies against CD44 (FL1) and TER119 (FL2) and 
definition of subpopulations (C). (A) In TER119 positive bone marrow cells four distinct 
subpopulations could be distinguished based on CD44 staining intensity and forward 
scatter (FL1 INT vs. FS INT plots). These populations are labeled I, II, III and IV. Note 
that only in !3-/- mice more cells are found in population III than IV (arrows, cf. also to 
fig. 4C). In contrast, in spleen cells (B) only three subpopulations could be distinguished 
with the CD44 and TER119 antibodies. The population labels correspond to those in (A). 
(C) Cells found primarily in May-Grunwald stained cytospin preparations of the 
subpopulations defined in (A) and (B) after FACS. Subpopulation I corresponded to ProE 
and Ery.A, II to EryA, III to some EryB and mainly Ery.C as defined by Liu et al. (Liu, et 
al 2006) and IV mainly to reticulocytes but also some erythrocytes similar to the 
definition from Chen et al. (Chen, et al 2009). 
 
S-fig 7. (A) Examples of immunofluorescence against fibronectin (original magnification 
200x). (B) Illustration of the quantification procedure. Using an image analyzing system 
a threshold 20% above the average background optical density level (oDL, 0 = black, 255 
= white) was defined. A circular sample tool was used to measure each single vessel in 
the images separately. The threshold procedure defined the pixels representing each 
single vessel (red). Then the average oDL (8-bit grayscale, 0 = black and 255 = white) of 
each vessel was calculated. 
 
S-fig 8. (A) Representative #CT images of the distal femur of all mouse lines 
investigated. Trabecular bone (red) had been detected user independently by software (cf. 
methods). Note the reduced volume density of the trabecular bone in the tg6 mouse. (B) 
Quantification of the trabecular bone structure. Trabecular thickness was the same among 
all mouse lines. Tg6 mice showed a significantly decreased trabecular number, which 
resulted in increased trabecular spacing. This suggests expanded space for erythopoietic 
cells (n " 3). (C) Examples of hematoxylin and eosin stained bone sections. No 
differences regarding the trabecular or cortical bone structure were found in !3-/- mice. 
Bone marrow in tg6 mice appeared to contain more cells than wt controls. 
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CHAPTER 3. CONCLUSION AND PERSPECTIVES
Normal erythropoiesis takes place mainly in specialized microanatomical niches
termed EI that are composed of a central macrophage with erythroblasts and premature
reticulocytes attached (43). This close association of erythroblasts with the central
macrophage is necessary for the maturation of erythroblasts (42) and crucially dependent on
molecules contributing to the interaction of macrophage and erythroblasts. Many different
molecules mediating both erythroblast/erythroblast and erythroblast/macrophage interactions
have been identified, such as EMP, ICAM-4, VCAM-1 and integrins. Of specific interest for
the present study was the fact that red cell ICAM-4 is important for the formation and stability
of EIs (51) but also that the counterreceptor on the central macrophage was not well defined
yet. In vitro, αv integrin was found to be expressed in macrophages isolated from EI and the
ICAM-4/αv interactions is critical for EI integrity. However, since integrins are only
functional as heterodimers composed of an α and a β subunit (261), we asked, what could be
the heterodimerization partner of αv integrin on central macrophages mediating attachment of
erythroblasts.
Previously, ICAM-4 on red cells was found to be the receptor of αvβ3 and αIIbβ3
integrin heterodimers, both present on platelets (283). Furthermore, critical amino acids in the
binding sites of human cell ICAM-4 with αvβ3 integrins have been identified (283). These
previous observations suggested that integrin β3 may contribute to the interaction with
ICAM-4 also in EIs. Thus, the lack of integrin β3 could disturb the stabilization of
erythroblastic island. This question was addressed in the present study using integrin β3-/-
mice in comparison to mice constitutively overexpressing EPO, which results in hematocrit
values of up to 90%.
Despite being reported to suffer from chronic gastrointestinal bleeding due to impaired
thrombocyte function (279), hematocrit, spleen size, plasma EPO level and RBC lifespan
were rather marginally altered in β3-/- mice suggesting that erythropoiesis is only mildly
stimulated in these mice. Flow cytometric measurement of erythrocyte size and peripheral
blood smears did not indicate any morphological abnormality of erythrocytes in β3-/- mice.
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Furthermore, β3 lacking mice did in contrast to tg6 mice no show reduced bone mass as
assessed by quantitative µCT analysis of the trabecular bone. Thus, these data indicate less
erythropoietic stimulation in β3 lacking mice compared to EPO overexpressing ones (tg6) that
exhibit maximally stimulated erythropoiesis as shown previously (280, 281,282).
However, when analyzing peripheral blood of β3-/- and tg6 mice regarding reticulocyte
staining intensity, CD47 expression and, band 4.1a / 4.1b ratio we found that peripheral blood
of integrin β3 lacking mice contains more immature peripheral erythrocytes than that of tg6
mice. Of note, in contrast to tg6 mice peripheral red cells of β3-/- mice even retained calnexin,
a protein that is normally completely lost during maturation of the reticulocytes before they
are released to the circulation. In addition, flow cytometric measurements of erythroblast
developmental stages in bone marrow from β3 lacking but not from EPO overexpressing tg6
mice revealed a reduced percentage of latest stage erythroblasts. Moreover, in β3 lacking but
not tg6 mice the number of erythroblasts per EI was also reduced. These data led to the
conclusion that integrin β3 might play an important role for the stabilization of EIs and that
the lack of β3 integrin could result in preterm release of immature reticulocytes into
circulation.
Taken together, by comparing stress erythropoiesis in two genetically modified animals
(β3-/- and tg6 mice), we discovered a new functional role of integrin β3 for stabilization of
erythropoietic islands. β3 integrin appears to be important especially during the very late stage
of red cell maturation by delaying release of premature reticulocytes. Interestingly, neoplastic
diseases of the erythroid linage are characterized by abnormally immature peripheral red cells,
which might be due to a disturbed expression pattern of adhesion molecules in the neoplastic
cells resulting in decreased EI stability. Whether this is indeed the case and whether tests
regarding calnexin expression on peripheral erythrocytes or staining intensity of reticulocytes
might be useful in detecting early stages of neoplasias of the erythroid linage should be
addressed in future studies.
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PREFACE
This part contains
1. A published article named “What is the optimal anesthetic protocol for measurements of
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Abstract Autoregulation, an important feature of the
cerebral circulation, is aVected in many diseases. Since
genetically modiWed mice are a fundamental tool in bio-
medical research, including neuro(bio)logy also in this spe-
cie measurements of cerebral autoregulation (CA) are
mandatory. However, this requires anesthesia that unfortu-
nately signiWcantly impacts cerebral perfusion and conse-
quently might distort CA measurements directly or by
altering arterial pCO2. The latter can be avoided by artiW-
cial ventilation but requires several control measurements
of blood gases, each consuming at least 100 !l of blood or
5% of a mouse’s blood volume. To avoid such diagnostic
hemorrhage, we systematically analyzed the eVect of diVer-
ent common anesthetic protocols used for rodents in spon-
taneously breathing mice on CA measured with Laser
speckle perfusion imaging. Halothane, IsoXurane and Pen-
tobarbital abrogated CA and Ketamin/Xylazine as well as
Chloralose had a moderate reproducibility. In contrast, the
rather rarely used anesthetic Ethomidate applied in low
doses combined with local anesthetics had the best repro-
ducibility. Although with this anesthesia the lower CA limit
was lower than with Ketamin/Xylazine and Chloralose as
reported in the handful of papers so far dealing with CA in
mice, we suggest Ethomidate as the anesthetic of choice for
CA measurements in spontaneously breathing mice.
Keywords Cerebral blood Xow · Laser Doppler 
Xowmetry · Cerebral circulation · Pial arteries · 
Anesthetics · Mice
Introduction
Normally, in the brain, perfusion and local metabolic
demand are closely linked (Kuschinsky 1990, 1991), and as
long as the metabolic demand of the brain remains con-
stant, a homeostatic regulatory mechanism called cerebral
auto-regulation (CA) allows the cerebral blood Xow (CBF)
to remain relatively constant during variations in arterial
blood pressure (Paulson et al. 1990). When CA is abol-
ished, Xuctuations of arterial blood pressure are accompa-
nied by either passive reduction or increase in CBF, leading
to syncope and falls, severe cerebral ischemia and edema
(Faraci and Heistad 1998). Mostly, disturbed CA is due to
chronic hypertension (Immink et al. 2004) resulting in
higher CA limits thereby making chronic hypertensive
patients highly vulnerable to brain ischemia in response to
unforeseen hypotension (Strandgaard 1976). Although the
upward shift of the CA limits in chronic hypertension has
been described many years ago (Vorstrup et al. 1984;
Harper 1987; Werber et al. 1990), its cause(s) are still
poorly understood. However, genetically modiWed mice
raise new options to answer also this question. Thus, there
is a certain need for a reliable technique to measure CA in
mice.
Measurements of the CBF response to blood pressure
changes consider either dynamic or static CA (Panerai
2008). Dynamic CA is a transient response to spontaneous
Xuctuations in systemic arterial blood pressure, changes in
posture or other maneuvers resulting in a sudden blood
pressure change. In man, dynamic CA can be assessed with
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transcranial Doppler ultrasound and (noninvasive) blood
pressure recordings together with wavelet analysis (Novak
et al. 2004; Hu et al. 2008; Lo et al. 2008). Unfortunately,
such a technique is not available for mice. In rodents
including mice, dynamic CA can be assessed by carotid
clamping (Rosengarten et al. 2006; Schubert et al. 2008).
Static CA is deWned as the steady-state relationship
between CBF and mean arterial blood pressure character-
ized in humans by a constant CBF between mean arterial
blood pressures of approximately 50 and 150 mmHg. Static
CA is measured in experimental animals using Laser Dopp-
ler Xowmetry after exposure of the skull or brain surface
together with manipulations of the blood pressure by con-
trolled bleeding (until complete exsanguination) sometimes
combined with phenylepinephrine infusion via catheters
inserted to the femoral vessels. It is obvious that such mea-
surements require suYcient anesthesia. However, anesthet-
ics themselves inXuence the reactivity of the brain
arterioles either directly e.g. volatile anesthetics dilate
arteries due to attenuation of Ca2+ entry through voltage-
gated Ca2+ channels on vascular smooth muscle cells
(Bosnjak et al. 1992) or, especially in spontaneously breathing
animals, indirectly by respiratory depression that increases
arterial pCO2. Brain vessels are very sensitive to CO2, and
therefore, increased pCO2 values are accompanied by cere-
bral vasodilatation (Kuschinsky 1997) and failure of CA.
The impact of the arterial pCO2 becomes even more obvi-
ous when considering reports showing that the CA dis-
turbed by IsoXurane anesthesia could be improved by
hypocapnia (McCulloch et al. 2005). Although the CO2
problem can be circumvented by artiWcial ventilation of the
animal, the latter introduces an additional trauma and
lengthens surgery. More importantly, the adjustment of the
respirator requires several blood gas analyses, each of it
consuming at least 100 !l blood. In larger animals, such as
rats, this is no problem, but in mice 100 !l equals about 5%
of the total blood volume. In mice blood loss, prolonged
operations and increased operative trauma per se easily dis-
tort the blood acid base status, most evident from a drop in
base excess (own unpublished observations). The reduced
base excess is either accompanied by a drop in arterial pH
and/or compensatory decrease of the arterial pCO2.
Since pial arteries are also sensitive to hydrogen ions
(Kuschinsky 1982), both changes again inXuence either way
the constriction state of brain arterioles.
The present study aimed to systematically evaluate
diVerent commonly used anesthetic protocols on static CA
in spontaneously breathing mice. SpeciWcally, for measure-
ment of CA in rats Barbiturates (Merzeau et al. 2000;
Paterno et al. 2000), volatile anesthetics such as Halothane
(Verhaegen et al. 1993; Pedersen et al. 2003) or IsoXurane
(Ayata et al. 2004; Tonnesen et al. 2005), Ketamine/Xyla-
zine, Chloralose urethane (Niwa et al. 2002) or Chloralose
alone (Ayata et al. 2004; Rosengarten et al. 2006) have
been used. In general, in the mentioned studies, the rats
were artiWcially ventilated. In a previous study with a set-
ting that is very sensitive to impaired cerebral vasoreactiv-
ity on spontaneously breathing rats, we were using
Ethomidate (Vogel and Kuschinsky 1996) that is known to
have relatively little eVect on CBF (Janssen et al. 1975;
Famewo and Odugbesan 1978). The present study shows
that Ethomidate provides the most consistent measure-
ments, appears to preserve the cerebral vasoreactivity best
and is thus recommended as the anesthetic of choice for CA
measurements in spontaneously breathing mice.
Methods
All experiments were performed on C57Bl6 mice and con-
formed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH Publication No. 85–23, revised 1996) and institu-
tional guidelines and were approved by the Cantonal Veter-
inary Department, Zurich, Switzerland. Since there was no
gender diVerence for any anesthetic protocol, mice of both
genders were used for the study except for telemetric blood
pressure and heart rate measurements where only males
were used.
Generally, the same anesthetic was used for surgery and
the subsequent experiments. Since in case of Ethomidate
this is not possible, surgery was performed during IsoXu-
rane anesthesia (2–2.5%) and the animals were allowed to
adapt for at least 30 min after discontinuing IsoXurane and
commencing the Ethomidate infusion before the CA mea-
surements were started. All anesthetic protocols are sum-
marized in Table 1. During surgery and the subsequent
experiment, the body temperature of the animals was
kept constant at 37°C using a temperature controlled
heating pad.
After induction of anesthesia, the mice were equipped
with catheters in both femoral arteries and veins for the
measurement of blood pressure, heart rate (PlugSys, Hugo
Sachs Electronics, Germany and PowerLab, ADInstru-
ments, Germany), blood gases and acid–base status
(AVL700, Radiometer Medical, Denmark) and hematocrit
and the infusion of anesthetics (cf. Table 1) and phenylepi-
nephrine. Before closing the wounds, a drop of 2% Lidoc-
ain (Streuli, Switzerland) was applied to the wound.
Thereafter the mice were placed in a stereotactic frame, the
scull was exposed and Xushed with 2% Lidocain. Then a
Laser speckle perfusion imager (moorFLPI, Moor Instru-
ments, UK) was adjusted to its maximal magniWcation and
Wve regions of interest (ROI’s, 3 on the left and 2 on the
right hemisphere) were deWned avoiding visible vessels. In
accordance with others (Ayata et al. 2004), preliminary
Author's personal copy
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experiments have shown that the transparency of the scull
of mice is high enough to not reduce signiWcantly the laser
signal as long as it is kept wet with artiWcial cerebrospinal
Xuid or 0.9% saline warmed to 37°C. The images were
acquired at 25 Hz and the traces of the ROI’s were sampled
with a time constant of 0.5 s. During surgery and the subse-
quent measurements of static CA, animals were allowed to
breathe pure oxygen spontaneously.
At the very beginning of the recordings, a screwdriver
handle was dropped onto the arterial line connected to the
blood pressure transducer. This produced an artifact simul-
taneously in both the blood pressure and the laser perfusion
trace that was later used to synchronize both traces for
oZine calculation of the CA limits. Then the mice were
slowly exsanguined via the second arterial line while con-
tinuously recording the laser speckle perfusion and blood
pressure signal. The exsanguination rate was adjusted man-
ually by continuous inspection of the blood pressure trace
to get a linear and constant decrease of the blood pressure
(about 1 mmHg/min, total exsanguination time: 35–40min).
In addition, some animals anesthetized with Ethomidate,
Chloralose or Ketamine/Xylazine received an infusion of
phenylepinephrin (Sintetica, Switzerland, 1 ng/g/min) that
was started 3 min before starting the CA measurement and
lasted until its end.
For determination of the CA limits, all laser speckle per-
fusion and blood pressure values before the marker artifact
were discarded and then the data were averaged in ten-sec-
ond intervals using macros written in Excel (Microsoft).
The laser speckle perfusion values obtained this way were
then plotted as a function of the corresponding blood pres-
sure values. Then the lower CA limit was determined by
linear extrapolation by starting with the lowest blood pres-
sure values and the upper limit in a similar way by starting
with the highest blood pressure values as described elsewhere
for the “plateau constraint” (Pedersen et al. 2003). This was
done separately for each of the Wve ROI’s. The Wnal CA
limits for each animal were deWned as the mean of those
determined for each ROI, and these mean values were used
for statistical analysis. The intra-individual variation of the
ROI’s was very low (coeYcient of variation: 1.3–2.8%).
Another experimental group was equipped with telemet-
ric blood pressure sensors (TA11PA-C10 transmitter, Data-
Sciences International, USA) as described recently (Schuler
et al. 2009, 2010) to assess the eVect of anesthesia on arte-
rial blood pressure and heart rate in comparison with con-
scious animals. In an additional control experiment, the
eVect of switching from normal air to pure oxygen on Laser
speckle imaging during IsoXurane and Ethomidate anesthe-
sia has been assessed.
Data are presented as means § standard deviation and
were analyzed with the GraphPad PRISM 4 Software
(version 4.01) using ANOVA and Students t test or
Kruskal–Wallis test (in case the number of values were not
equal for all groups) for unpaired samples with Bonferroni’s or
Dunn’s post hoc test, respectively. P values of <0.05 were
considered signiWcant.
Results
Table 2 shows the physiologic variables of all naïve ani-
mals used for the study. The blood gas values of mice
treated with phenylepinephrine were similar, but mean arte-
rial blood pressure as well as heart rate were considerably
higher by 53 and 61%, respectively (not shown). The most
striking diVerence between the groups of naïve mice was
found concerning the arterial pCO2 with highest values in
Pentobarbital and Ketamine/Xylazine anesthetized mice
and lowest during IsoXurane anesthesia. In addition, heart rate
Table 1 Anesthetic protocols
a After Wnishing the preparation during IsoXurane anesthesia
b 16.6 mg Chloralose dissolved together with 25 mg sodiumtetraborate * 10H2O/ml H20
c After Wnishing the preparation changed to i.v. application
Active component Trade name Provider Route Initial dosage Maintenance dosage
Ethomidate Ethomidate 
Lipuro
B. Braun Medical AG, Sempach, 
Germanya
i.v. 80 !g/min 
for 3 min
14–26 !g/min
Ketamine/Xylazine Rompun/
Narketan
Ratiopharm, Ulm, Germany/Bayer, 
Leverkusen, Germany
i.p. 90 mg kg¡1/
9 mg kg¡1
40 mg kg¡1 every 
30 min/4 mg kg¡1 
every 30 min
Alpha-chloralose Siqma-Aldrich GmbH, Buchs, 
Switzerlandb, c
i.p./i.v. 25 mg kg¡1 75 mg kg¡1 h¡1
IsoXurane IsoFlo Abbott AG, Baar, Switzerland Inhalation 5% 1.50%
Haiotnane Halothane Arovet AG, Zollikon-Station, Switzerland Inhalation 4% 0.90%
Pentobarbital Vetanarcol Veterinaria AG, Zurich, Switzerlandc i.p./i.v 100 mg kg¡1 1 mg kg¡1 h¡1
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is lower in those anesthetic regimes that result in respira-
tory depression such as Ketamine/Xylazine and Pentobar-
bital. Most likely this is an eVect of hypercapnia that has
been shown to induce bradycardia in mice (Campen et al.
2004). The high pO2 values in all experimental groups are
due to pure oxygen breathing. The telemetric blood pres-
sure and heart rate data had been obtained in the context
of a recent study (Schuler et al. 2010). In comparison with
these data, all anesthetics reduced blood pressure and
heart rate. Switching from air to pure oxygen did not
aVect the blood pressure or the Laser speckle signal (data
not shown).
Figure 1 shows example autoregulation curves (mean of
all ROIs of a single animal) of all anesthetics tested without
parallel phenylepinephrine infusion. Halothane as well as
IsoXurane resulted in complete abrogation of CA that is for
IsoXurane in agreement with previous reports (Ayata et al.
2004). A bit surprisingly, since also used in several studies
dealing with CA, Pentobarbital anesthesia also was associated
with a complete loss of CA. This is most probably due to
the anesthesia-induced hypercapnia of the spontaneously
breathing mice (cf. Table 2).
In Ketamine-/Xylazine- and Chloralose-anesthetized mice,
the lower CA limit was around 44 and 53 mmHg, respec-
tively, which is in agreement with previous reports on mice
investigated using Chloralose (Ayata et al. 2004). In con-
trast, the lower CA limit in Ethomidate-anesthetized mice
was considerably lower at around 25 mmHg and the drop
was more abrupt than in Ketamine-/Xylazine- or Chloralose-
anesthetized mice (cf. Fig. 1). However, in naïve ani-
mals, the diVerences in lower limit of CA reached statistical
signiWcance only for the comparison between Ethomi-
date and Chloralose. For Ethomidate, Ketamine/Xylazine
and Chloralose, the lower limit was also determined during
phenylepinephrine infusion resulting in the same limits
(Fig. 2); however, between these groups, none of the diVer-
ences were statistically signiWcant. This is most likely
due to much larger data scatter in Ketamine/Xylazine and
Fig. 1 Representative examples of autoregulation curves (mean of all
Wve ROI’s of a single animal) obtained with the diVerent anesthetics
as indicated. The anesthetics shown on the right completely abrogated
cerebral autoregulation (CA). For Ethomidate, the range of CA is larg-
est. Also in Ketamine-/Xylazine-anesthetized mice, the lower as well
the upper CA limit can be seen, whereas in Chloralose-anesthetized
mice, the upper limit is not visible since with falling blood pressure
cerebral perfusion is reduced rather in an exponential fashion until the
lower CA limit is reached
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Chloralose anesthetized mice compared to those anesthetized
with Ethomidate. Accordingly the coeYcient of variation
was between 3- and 3.9-times lower during Ethomidate
anesthesia than during Ketamine/Xylazine and Chloralose
anesthesia. These latter data indicate that Etomidate has
the best reproducibility concerning the measurement of the
lower CA limit.
Regarding the upper limit in some animals of all anesthetic
protocols, the determination was not possible since above
the lower limit the CA curves showed an exponential shape.
This was even more the case in phenylepinephrine-treated
mice. However, the best detection rate of an upper limit
was found in Ethomidate-anesthetized mice. In contrast
to the lower limit, there were no major diVerences in the
upper limit between naïve mice anesthetized with Ethomi-
date, Ketamine/Xylazine or Chloralose. In phenylepineph-
rine-treated mice, the upper limit tended to be higher during
Ketamine/Xylazine and Chloralose anesthesia. In contrast to
the lower limit, the measurements of the upper limit
appeared to be more stable (maximum coeYcient of variation
of about 22%) irrespective of the fact that sometimes the
upper limit could not be determined at all.
By taking the measurements of the lower and upper
limits together in naïve Ethomidate anesthetized mice, the
CA range was considerably larger (42 mmHg vs. 9.9 and
19.2 mmHg during Ketamine/Xylazine and Chloralose
anesthesia). During phenylepinephrine treatment, the
diVerences between lower and upper limit were quite sim-
ilar (34.6, 35.6 and 36.8 mmHg). The latter data however
are based only on a few mice and thus should be taken
with caution.
In addition, we aimed to assess the vasodilatation
induced by the anesthetics themselves as well as the vasodi-
lator capacity (deWned as the diVerence between the initial
and maximum perfusion per mmHg) in response to the fall-
ing blood pressure during the diVerent anesthetic protocols.
Although Laser speckle perfusion imaging does provide
only semi-quantitative data, the measurements are quite sta-
ble as determined with a motility standard provided by the
manufacturer of the imager along with the device. Thus, we
calculated the initial Laser speckle perfusion/mmHg before
exsanguination was started. In addition, we calculated the
diVerence between the initial perfusion/mmHg and the
maximal perfusion/mmHg before the Wnal drop of the cere-
bral perfusion. In case there was no increase observed from
the initial value, the perfusion/mmHg value at a blood pres-
sure of 50 mmHg was taken. Figure 3 shows that there were
large diVerences in the initial perfusion between the diVer-
ent anesthetics with a maximum factor of nearly 3 between
Ethomidate and Halothane. Note that Halothane, IsoXurane,
and Pentobarbital, which abrogated CA, exhibit the highest
initial laser speckle perfusion as well as perfusion/mmHg
values. This indicates anesthesia-induced vasodilatation. In
line with this, the maximal increase in perfusion/mmHg as
a result of the falling blood pressure was found also in
Ethomidate-anesthetized mice (Fig. 4). In contrast, in Halo-
thane-, IsoXurane-, and Pentobarbital-anesthetized mice,
sometimes no increase at all could be observed but rather a
continuous decrease of perfusion/mmHg from the very
beginning until the end of the experiments. These Wndings
indicate that Halothane, IsoXurane as well as Pentobarbital
abrogate the vasoreactivity of brain vessels in spontane-
ously breathing mice and are therefore unsuited for CA
measurements in this specie.
Fig. 2 Mean lower (a) and upper (b) CA limits determined mice with
and without phenylepinephrine treatment. a The lower CA limit was
the same with or without phenylepinephrine treatment but lowest dur-
ing Ethomidate anesthesia. However, this was statistically signiWcant
only compared to Chloralose (both untreated, *P < 0.05), most likely
due to the high data scatter in the Ketamine/Xylazine and Chloralose
groups as indicated by the coeYcient of variation (numbers in the Wrst
row). The more than 3-times smaller coeYcient of variation indicates
a better reproducibility during Ethomidate anesthesia compared to
both, Ketamine/Xylazine and Chloralose. b Determination of the up-
per limit was hampered by the fact that some traces showed an expo-
nential shape above the lower CA limit (cf. Fig. 1, Chloralose). In
keeping with this limitation, the upper CA limits in Ketamine-/Xyla-
zine- and Chloralose-anesthetized animals tended to be higher in case
of phenylepinephrine treatment in contrast to Ethomidate-anesthetized
mice. In Ketamine-/Xylazine- and Chloralose-anesthetized mice, the
coeYcient of variation was lower than that for the lower CA limit and
in Ethomidate-anesthetized mice similar to that of the lower limit.
*P < 0.05 vs. Chloralose + phenylepinephrine, means§ SD, N = number
of animals per group
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Discussion
The present study clearly indicates that in spontaneously
breathing mice, the anesthetic protocol for measurement of
CA aVects both the absolute values as well as the reproduc-
ibility of the measurements. In view of the high value of
transgenic mice which are often also costly pre-treated
before CA is Wnally measured, good reproducibility is an
important point in choosing the anesthetic protocol to
detect small but nevertheless biologic relevant diVerences
between experimental groups. Here, we show that Ethomi-
date has an excellent reproducibility and retains reactivity
of the cerebral vasculature best. Therefore, from all anes-
thetics tested in the present study, Ethomidate appears to be
the anesthetic of choice for the measurement of CA in
spontaneously breathing mice.
The best way to exclude any inXuence of anesthetics on
mice appears to measure CA in the conscious state
(Lacombe et al. 2005; Joutel et al. 2010). In these papers,
the perfusion was quantiWed with Laser Doppler Xowmetry
via optical Wbers glued to the scull of mice also equipped
with catheters inside the femoral vessels. The animals had
been placed in restrainers for 2 h before starting the Wnal
measurements. Laser speckle perfusion imaging that has
been used in the present study, however, requires the scull
to be Wxed since it cannot distinguish tissue from red cell
movements. In addition, restraining animals equipped with
optical probes at the scull and catheters inside the femoral
Fig. 3 Initial laser speckle per-
fusion (white bars) and initial 
perfusion normalized to the 
mean arterial blood pressure 
(gray bars). These data should 
be indicative for the vasodilata-
tion state induced by the diVer-
ent anesthetics. Halothane, 
IsoXurane, and Pentobarbital 
that abrogated CA have the high-
est initial laser speckle perfusion 
as well as perfusion/mmHg val-
ues. I IsoXurane, 
P Pentobarbital, H Halothane
Fig. 4 DiVerence between the 
initial perfusion/mmHg and the 
maximal perfusion/mmHg. In 
contrast to Ethomidate, Keta-
mine/Xylazine and Chloralose 
anesthetized mice in Halothane, 
Pentobarbital and IsoXurane 
anesthetized mice more (Halo-
thane) or less often (IsoXurane) 
no increase at all from the initial 
perfusion/mmHg value could be 
observed. In such a case, the per-
fusion/mmHg value at a blood 
pressure of 50 mmHg was taken. 
These data indicate that the high-
est vasodilatation reserve is 
present during Ethomidate anes-
thesia. E Ethomidate, 
K Ketamine/Xylazine, 
C Chloralose
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vessels, even when treated with local anesthetics, for such a
long period with Wnal exsanguinations in the conscious
state is diYcult to get permitted in countries with strong
animal protection laws such as Switzerland. Nevertheless
CA measurements in conscious mice might allow assessing
where the real limits are lying in this specie. In the afore-
mentioned papers, the CA limits were determined in a
diVerent way when compared to the present study. These
authors deWned the lower limit as 90% and the upper limit
as 110% of the initial blood Xow. This way they obtained in
wt mice a lower limit of about 60 mmHg, a value that is
15–20 mmHg above those reported by others for Ketamine/
Xylazine and Chloralose (Niwa et al. 2002; Ayata et al.
2004; Tonnesen et al. 2005; Rosengarten et al. 2006) and
that of the present study using the same anesthetics. How-
ever, when trying to apply the method for calculating the
lower limit used in the present study (Pedersen et al. 2003)
to the data of Lacombe et al. (2005) and Joutel et al. (2010)
a lower limit of about 40–45 mmHg appears to be present
also in their data. Thus, the lower CA limit in conscious
mice is most close to our values and those of others
obtained during Ketamine/Xylazine and Chloralose anes-
thesia. In Ethomidate-anesthetized mice, however, the
lower limit is clearly lower, although there was only minor
signiWcance to the other anesthetics most likely due to
much high data scatter in the Ketamine-/Xylazine- and
Chloralose-anesthetized groups (cf. coeYcients of varia-
tion, Fig. 2a). Concerning the upper limit, Lacombe et al.
(2005) found during phenylepinephrine infusion and using
their 110% method a value of 120 mmHg. Again when
applying the method of the present study for determining
the upper limit to their data the upper limit appears to be
diVerent, namely about 90 mmHg. Thus, the range of CA in
mice appears to be about 40 mmHg. In naïve mice, a simi-
lar CA range was found only for Ethomidate-anesthetized
mice, whereas in Ketamine-/Xylazine- and Chloralose-
anesthetized mice, the range was 4- and 2-times smaller,
respectively. In contrast, in phenylepinephrine treated mice,
the CA range was not diVerent between the diVerent anes-
thetic protocols and with 35 mmHg also comparable to that
found in naïve Ethomidate-anesthetized mice and that esti-
mated from the data of conscious mice (Lacombe et al.
2005). Thus, Ethomidate appears to preserve the CA range
best but to shift the autoregulation curve slightly leftward.
In contrast, in naïve Ketamine-/Xylazine-and Chloralose-
anesthetized mice, the CA range was clearly reduced sug-
gesting an impaired vaso-reactivity that is also evident from
the reduced maximal perfusion change per mmHg in
response to the blood pressure drop (cf. Fig. 4). This is also
in line with the lowest initial perfusion per mmHg in
Ethomidate anesthesia (cf. Fig. 3), indicating a higher ini-
tial cerebrovascular constriction state and thus a higher
vasodilatatory reserve.
Concerning Halothane only studies in rats could be
found (Verhaegen et al. 1993; Pedersen et al. 2003), but
Halothane slowly disappears from the market. In principle,
the pharmacological action of Halothane is similar to that
of IsoXurane but the wash-in and -out of IsoXurane is faster
(Yasuda et al. 1989) enabling better control of the anesthe-
sia. Thus, in recent years, IsoXurane became the standard
volatile anesthetic also in animal research and was used in
rats and mice for the measurement of cerebral blood Xow
under diVerent conditions including functional stimulation
(Ayata et al. 2004; Joutel et al. 2010) and cerebral autoreg-
ulation (Ayata et al. 2004; Tonnesen et al. 2005). One paper
directly compared in mice IsoXurane with Choralose con-
cerning CA as well as functional stimulation (Ayata et al.
2004) and found according to our results an abrogation of
CA during IsoXurane anesthesia. In contrast, functional
stimulation was not diVerent between IsoXurane and Chlo-
ralose that is in line with the data of others also reporting in
mice a preserved functional stimulation during IsoXurane
anesthesia (Lacombe et al. 2005; Joutel et al. 2010) at an
inspired concentration of 1.2–1.5%. We did not yet test Iso-
Xurane and functional stimulation in mice, but previously in
a study on rats, we used Ethomidate (Vogel and Kuschin-
sky 1996) because any functional stimulation-related CBF
eVect was abolished during Halothane anesthesia. This is in
line with studies showing that the reactivity of the smooth
muscle is impaired by volatile anesthetics (Bosnjak et al.
1992) as well with the data of the present study showing
that IsoXurane like Halothane results in a complete loss of
CA (cf. Fig. 1). However, a study dealing with the ortho-
static regulation of mice claimed that CA was preserved
during 1% IsoXurane anesthesia (Foley et al. 2005). With-
out measuring CA directly, this was concluded from the
fact that phenylepinephrine increased mean arterial blood
pressure but not CBF. However, phenylepinephrine results
in a considerable tachycardia (in the present study by 61%)
that in turn impairs cardiac output. Thus, an increased mean
arterial blood pressure during phenylepinephrine treatment
paralleled by a reduced cardiac output might leave CBF
unchanged independent of an autoregulatory action of the
cerebral vasculature.
The most signiWcant problem when using Pentobarbital
in spontaneously breathing animals is ventilatory depres-
sion that results in hypercapnia induced cerebral vasodilata-
tion and subsequent loss of CA (cf. Table 2 and Fig. 1). To
our knowledge, it has not yet been shown whether Barbitu-
rates have also direct (pCO2-independent) eVects on CA,
but dosages of pentobarbital previously published for para-
lyzed and artiWcially ventilated rats (Paterno et al. 2000)
were not suYcient to keep our mice in the tolerance state.
Consequently, we had to increase the dosage resulting in
the highest arterial pCO2 values of all groups. The present
study was designed to test the eVects of the diVerent anesthetic
Author's personal copy
Exp Brain Res (2010) 207:249–258 257
123
protocols in spontaneously breathing mice, because the
great disadvantage of artiWcial ventilation is additional
trauma and the necessity of several determinations of the
arterial blood gases to adjust the respirator. Each blood
gas determination requires at least about 100 !l of arte-
rial blood. Thus, 2–3 determinations of blood gases can
bring the animals close to a hemorrhagic shock. Although
the lost blood can be replaced, e.g., by saline, this
reduces the hematocrit and consequently the oxygen
transport capacity of the blood that in turn increases CBF
(Waschke et al. 1994). Of note, we supplemented the
mice during the experiments with pure oxygen. In con-
trast to the vasodilating eVect of hypoxia, CA is not
diVerent in man breathing either normal air or pure oxygen
(Ogoh et al. 2010). In line with this study, we found no
diVerence in the Laser speckle signal when switching from
air to pure oxygen.
Using anesthetics for CA measurements has the princi-
ple and unavoidable disadvantage of inXuencing CBF and
thus the CA measurement itself. In addition, anesthesia-
induced hypercapnia might disturb CA. The same hold for
intermittent sometimes un-recognized hypoxia that can
occur during anesthesia especially when induced by injec-
tions. Since the brain is very sensitive to shortage of oxy-
gen hyperoxia has been found to be very eVective as
emergency treatment in traumatic brain injury or stroke
(Kumaria and Tolias 2009). Because it drastically reduces
the risk of hypoxia during anesthesia but does not alter
brain perfusion (cf. previous paragraph), we recommend
supplying the mice with pure oxygen during surgery and
subsequent CA measurements. Although hypercapnia and
hypoxia can be avoided by artiWcial ventilation, this
requires several determinations of the arterial blood gases,
in mice easily resulting in a “diagnostic hemorrhage”. In
addition, one should be aware that transferability of data
from animal experiments to the clinics could be hampered
by the fact that diVerent researchers perform CA measure-
ments in a diVerent way. One underestimated diVerence
between protocols is anesthesia. Here, we aimed to Wnd an
anesthetic protocol that requires as little surgery as possi-
ble, to allow measurements in spontaneously breathing ani-
mals and has a high reproducibility. Such an anesthetic
protocol reduces uncontrolled inXuences of side parameters
on the data and thus increased the transferability of the data
into clinics. Reproducibility is also a very important point
in light of using valuable genetically modiWed mice that
might be available only in limited numbers e.g. due to
reduced breeding success. In this context also small system-
atic errors can be tolerated as long as the good reproducibil-
ity exceeds this disadvantage. Taken together, we feel that
Ethomidate is—of the anesthetics tested here—the best due to
its ability to keep the arterial pCO2 in the normal range without
the need of artiWcial ventilation, its excellent reproducibility,
and a CA range closest to that of conscious animals
(Lacombe et al. 2005; Joutel et al. 2010). The fact that
Ethomidate shifts the CA curve slightly leftward could
even be interpreted as an advantage, since this allows
catching also the upper CA limit without phenylepinephrine
treatment.
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